Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter

 
All Metastatic Trials

Istodax and Platinol for Advanced BRCA+ or Triple Negative Breast Cancer

Phase I/II Trial of Cisplatin Plus Romidepsin in Locally Recurrent or Metastatic Triple Negative Breast Cancer or BRCA1 or BRCA2 Mutation Associated Locally Recurrent or Metastatic Breast Cancer. (NCT02393794)

Summary

Romidepsin (Istodax®) is an FDA-approved drug that is currently used to treat a type of lymphoma. Laboratory studies suggest Istodax may also be effective for treating breast cancer. Cisplatin (Platinol®) is a platinum-based chemotherapy drug that studies suggest is effective for treating triple-negative breast cancer. In the first phase of the study, researchers will determine the highest dose of Istodax that can safely and tolerably be used in combination with Platinol. In phase II, this highest dose will be given along with Platinol. Both phases of the study will enroll women with advanced breast cancer who are known to carry a BRCA mutation or who have triple negative breast cancer.


This is a Phase I-II trial

MM-310 for Metastatic Triple Negative Breast Cancer

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors (NCT03076372)

Summary

To take part in this study, you must have metastatic triple negative (ER-/PR-/HER2-) breast cancer. This study will determine the best dose, safety and effect (good and bad) of a new type of targeted drug researchers think will be effective in patients with metastatic triple negative breast cancer. The new drug is called MM-310. It delivers the chemotherapy drug docetaxel (Taxotere®) directly to cancer cells. Results from this study will help researcher determine the best dose of MM-310 to use when it is combined with other anti-cancer drugs. This study is also enrolling patients with other types of solid cancers.


This is a Phase I trial

Carboplatin and Afinitor for Metastatic Triple-Negative Breast Cancer

A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer (NCT02531932)

Summary

Paraplatin (Carboplatin®) is a platinum-based chemotherapy drug used to treat metastatic breast cancer that has not responded to previous treatments. Everolimus (Afinitor®) is a type of targeted therapy called an mTOR inhibitor. It works by interfering with a cancer cell's ability to divide and grow. This study will compare the safety and effectiveness of Carboplatin and Afinitor to Carboplatin alone for treating metastatic triple-negative breast cancer.


This is a Phase II trial

Keytruda plus Taxol for Metastatic HER2-Negative Breast Cancer

LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial) (NCT03018080)

Summary

To take part in this study, you must have HER2-negative metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good and bad) of using the chemotherapy drug paclitaxel (Taxol®) along with the immunotherapy pembrolizumab (Keytruda®) to treat metastatic HER2-negative breast cancer. The researchers are studying two different treatment regimens. In one regimen, patients will receive Taxol followed by Taxol and Keytruda at the same time. In the other, patients will receive Taxol and Keytruda at the same time. Taxol is routinely used to treat breast cancer. Keytruda is approved to treat certain types of cancers.


This is a Phase II trial

Rebastinib plus Chemotherapy for Metastatic Breast Cancer

Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer(NCT02824575)

Summary

To take part in this study, you must have HER2-negative breast cancer that has spread to other parts of your body (metastatic). You must have already received chemotherapy. If your tumor is hormone-sensitive, you must have already taken an anti-estrogen drug. Rebastinib is a new drug that is available only in clinical trials. This study is looking at how well it works when it is given along with a chemotherapy drug. Rebastinib is a targeted drug. The chemotherapy drugs being used in this study are paclitaxel (Taxol®) and eribulin (Halaven®). Both are used to treat metastatic breast cancer. The researchers will look at what treatments you have already had to decide whether you should get Taxol or Halaven.


This is a Phase I trial

A Study of a New Drug (NKTR-102) in Breast Cancer Patients with Stable Brain Metastases

A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (NCT02915744)

Summary

To take part in this study, you must have metastatic breast cancer that has spread to your brain. You must have undergone prior radiation and/or surgery and the brain metastasis must be considered stable. You must also have been treated with an anthracycline, a taxane, and capecitabine (Xeloda®) at some point following your first diagnosis with breast cancer. This study is comparing the safety and effectiveness of a new chemotherapy drug to a Treatment of Physician's Choice in patients with metastatic breast cancer who have stable brain metastases. The new chemotherapy drug is called NKTR-102. It is only available in clinical trials. The Treatment of Physician's Choice will be selected from the following seven standard of care chemotherapies: eribulin (Halaven®), ixabepilone (Ixempra®), vinorelbine (Navelbine®), gemcitabine (Gemzar®), paclitaxel (Taxol®), docetaxel (Taxotere®) or nab-paclitaxel (Abraxane®). All of these drugs are routinely used to treat metastatic breast cancer.


This is a Phase III trial

Halaven & Cytoxan for Advanced Breast Cancer

A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (NCT01554371)

Summary

Combining two or more cancer drugs that work in different ways may be more effective than using one cancer drug at a time. Eribulin (Halaven®) is approved for treating metastatic breast cancer. Cyclophosphamide (Cytoxan®) is approved for treating many different types of cancer, including breast cancer. However, the combination of eribulin and cyclophosphamide is considered experimental. The purpose of this study is to test the safety and effectiveness of the two drugs when they are given together at different doses to patients with locally advanced or metastatic breast cancer (and other solid tumors).


This is a Phase I-II trial

TVB-2640 with Taxol and Herceptin for HER2+ Advanced Breast Cancer

Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Paclitaxel and Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab and Taxane-Based Therapy (NCT03179904)

Summary

To take part in this study, you must have HER2-positive, advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good and bad) of using a new targeted therapy along with a chemotherapy and a HER2-targeted therapy to treat HER2 positive advanced breast cancer. The new targeted therapy used in this study is TVB-2640. It stops cancer cells from growing by targeting a protein called FASN. The chemotherapy drug used in this study is paclitaxel (Taxol®). The HER2-targeted drug is trastuzumab (Herceptin®).


This is a Phase II trial

AZD8186 and Docetaxel for Advanced Breast Cancer with PTEN or PIK3C-beta Mutations

A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (NCT03218826)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer that will potentially respond to the chemotherapy drug docetaxel (Taxotere®).

This study will determine the best dose and effects (good and bad) of an experimental targeted therapy when it is used with a chemotherapy to treat tumors that test positive for PTEN or PIK3C-beta mutations. The targeted therapy is AZD8186. Taxotere is a chemotherapy commonly used to treat breast cancer. This study is also enrolling patients with other types of cancers.


This is a Phase I trial

Rebastinib and Paclitaxel in Women and Men with Metastatic Breast Cancer

An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors (NCT03601897)

Summary

To take part in this study, you must be a woman or man with metastatic breast cancer.

This study is evaluating the safety and effects (good and bad) of using the experimental drug rebastinib along with paclitaxel (Taxol®) in patients with metastatic breast cancer. Rebastinib is an investigational targeted therapy. Taxol is a chemotherapy drug used to treat breast cancer. This study is also enrolling women with ovarian cancer and endometrial cancer.


This is a Phase I-II trial

Ipatasertib and Taxol for HER2- Advanced Breast Cancer

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (NCT03337724)

Summary

To take part in this study, you must have advanced HER2- (some stage III) or metastatic (stage IV) breast cancer. This study is evaluating the safety and effects (good or bad) of using a new targeted therapy along with paclitaxol (Taxol®) for treating advanced HER2- breast cancer. The targeted therapy, ipatasertib (GDC-0068), blocks a protein called AKt that helps cancer cells divide and grow. Taxol is a chemotherapy drug routinely used to treat breast cancer.


This is a Phase II-III trial

Keytruda + Chemo or an Aromatase Inhibitor for HER2-Negative Metastatic Breast Cancer

MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer (NCT02648477)

Summary

Pembrolizumab (Keytruda®) is an immunotherapy drug that targets the programmed cell death (PD-1) protein. Blocking this protein allows the body's immune system to attack cancer cells. Doxorubicin (Adriamycin®) is a chemotherapy drug commonly used to treat breast cancer. Aromatase inhibitors (anastrozole/Arimidex®, letrozole/Femara®, exemestane/Aromasin®) are used to treat hormone-sensitive tumors in postmenopausal women. This study is investigating the safety and effectiveness of using Keytruda to treat HER2-negative metastatic breast cancer. In this study, patients with triple-negative tumors will receive Adriamycin along with Keytruda, while patients with hormone-sensitive tumors will receive an AI along with Keytruda.To be eligible, participants must not have been treated previously with Keytruda.


This is a Phase II trial

Ibrance with Cisplatin or Carboplatin for Advanced Breast (and Other) Cancer

A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies (NCT02897375)

Summary

To take part in this study, you must have been diagnosed with stage III or stage IV (metastatic) breast cancer.

This study is looking at the safety and effectiveness of two different drug combinations. All patients in this study will receive palbociclib (Ibrance®) with a chemotherapy drug, either cisplatin (Platinol®) or carboplatin (Paraplatin®). Ibrance is a new type of targeted drug called a CDK inhibitor. It is approved to treat postmenopausal women with ER-positive, HER2-negative metastatic breast cancer who have not already had an anti-estrogen drug. The two chemotherapy drugs, Platinol and Paraplatin, are are used to treat advanced breast cancer that has not responded to previous chemotherapy treatments.


This is a Phase I trial

Ribocilcib and Taxol in Metastatic Breast Cancer with the Rb Protein

A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer (NCT02599363)

Summary

Ribociclib (LEE011) is a type of targeted therapy called a cyclin-dependent kinase (CDK) inhibitor. It works by inhibiting two enzymes, CDK4 and CDK6, that help cancer cells grow. Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat breast cancer. Retinoblastoma (RB) is a tumor suppressor protein. Laboratory studies suggest targeting the Rb pathway by inhibiting the CDK4 and CDK6 enzymes may be an effective breast cancer treatment. This study will identify the best dose of ribociclib to use along with Taxol to treat patients with metastatic breast cancer. Interested patients will have their tumor tested for the Rb protein. Only those whose tumor tests positive for this protein will be eligible to enroll.


This is a Phase I trial

Galunisertib and Taxol for Metastatic Triple Negative Breast Cancer

A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer (NCT02672475)

Summary

Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat advanced breast cancer. Galunisertib (LY2157299) is a new type of targeted therapy. It works by blocking a protein called TGF-betaR1 kinase. This study will evaluate the best dose and safety of galunisertib and Taxol for treating patients with metastatic triple-negative breast cancer that also tests androgen-receptor negative.


This is a Phase I trial

Comparing Two Different Doses of Xeloda for Metastatic Breast (and GI) Cancer

Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers (NCT02595320)

Summary

Capecitabine (Xeloda®) is a chemotherapy drug used to treat metastatic breast cancer that has stopped responding to other chemotherapy drugs. Because it is an oral drug, it can be taken at home. This study is comparing the effectiveness and side effects associated with two different doses and dosing schedules of Xeloda in women with metastatic breast cancer. This study is also recruiting individuals with advanced/metastatic gastrointestinal cancer.


This is a Phase II trial

Tesetaxel and Capecitabine for HER2 negative, HR positive Advanced Breast Cancer

Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane (CONTESSA 2) (NCT03858972)

Summary

To take part in this study you must have locally advanced (some stage III) or metastatic (stage IV) breast cancer that is ER positive and HER2 negative and have not been previously treated with a taxane.

This study is investigating the effects (good or bad) of tesetaxel when used with a reduced dose of capecitabine (Xeloda®). Tesetaxel is a new type of taxane chemotherapy drug that can be taken by mouth. The taxanes that are currently approved are all given intraveneously (IV). Xeloda® is an oral chemotherapy drug approved to treat advanced breast cancer.


This is a Phase II trial

Keytruda with Chemotherapy for Metastatic Triple Negative Breast Cancer

A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer (NCT02755272)

Summary

To take part in this study, you must have metastatic triple negative (ER-/PR-/HER2-negative) breast cancer. Pembrolizumab (Keytruda®) is an immunotherapy drug that gets the immune system to seek out cancer cells. It is used to treat advanced melanoma and metastatic non-small cell lung cancer. Researchers want to learn how well Keytruda works with chemotherapy to treat metastatic triple negative breast cancer. In this study, Keytruda will be combined with two chemotherapy drugs currently used to treat advanced breast cancer that has not responded to other chemotherapy drugs: carboplatin (Paraplatin®) and gemcitabine (Gemzar®).


This is a Phase II trial

Keytruda with Taxol or Xeloda for Advanced Triple Negative Breast Cancer

A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients (NCT02734290)

Summary

This study is looking at the safety and effectiveness of using an immunotherapy drug along with a chemotherapy drug to treat breast cancer that cannot be removed by surgery. The immunotherapy drug is pembrolizumab (Keytruda®). It gets the body's immune system to go after cancer cells. The chemotherapy drug will be paclitaxel (Taxol®) or capacitabine (Xeloda®), depending on which group you are put in. Both drugs are commonly used to treat advanced breast cancer. To take part in this study, you must have advanced triple negative breast cancer.


This is a Phase I-II trial

Abraxane & Mifepristone in Advanced Triple Neg Breast Cancer with Glucocorticoid Receptors

A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (NCT02788981)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer. In addition, your tumor sample must test positive for glucocorticoid receptors (GR). This study will determine the safety and effects (good and bad) of using chemotherapy along with a steroid to treat advanced or metastatic triple negative breast cancer. The chemotherapy drug being used in this study is nab-paclitaxel (Abraxane®). It is approved to treat advanced breast cancer. The steroid being used in this study is mifepristone. Researchers believe blocking the glucocorticoid receptor may make chemotherapy more effective.


This is a Phase II trial

INT230-6 Injections & Immunotherapy for Treating Advanced Breast Cancer

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers (NCT03058289)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and have at least one tumor that can be felt by your doctor or seen on a scan by your radiologist. You also must have tried all other available treatments. INT230-6 is a combination chemotherapy treatment that is injected directly into the tumor. The first part of this study will determine the best dose of INT230-6. The second part will investigate how tumors respond to the best dose of INT230-6 when it is given with an anti-PD-1 immunotherapy. INT230-6 contains the chemotherapy drugs cisplatin (Platinol®) and vinblastine (Velban®) along with a substance that makes them more effective. This study is also recruiting patients with other types of advanced cancers.


This is a Phase I-II trial

Keytruda and Abraxane in HER2 Negative Metastatic Breast Cancer

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer (NCT02752685)

Summary

Researchers are trying to see which treatment combinations are best for HER2 negative breast cancer. This study is looking at the safety and effectiveness of using a chemotherapy drug along with an immunotherapy drug. The chemotherapy drug is nab-paclitaxel (Abraxane®), which is used to treat advanced breast cancer. The immunotherapy drug is pembrolizumab (Keytruda®), which gets the immune system to go after cancer cells. To take part in this study, you must have metastatic breast cancer that is HER2-negative.

L-NMMA plus Taxotere for Advanced Triple Negative Breast Cancer

Clinical Phase Ib Trial of L-NMMA Plus Docetaxel in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (NCT02834403)

Summary

Scientists have created new drugs to treat triple negative(ER-, PR-, HER2-) breast cancer. One of these new drugs is called L-NMMA. In this study, researchers will determine the best dose, safety and effectiveness of L-NMMA when it is given with a chemotherapy drug that is used to treat advanced breast cancer. The chemotherapy drug being used is docetaxel (Taxotere®). L-NMMA targets the NOS (nitric oxide synthase) inhibitor. To take part in this study, you must have metastatic triple negative breast cancer or stage III triple negative breast cancer that has already been treated with at least one other chemotherapy drug.


This is a Phase I-II trial

Platinol plus Veliparib for Recurrent or Metastatic HER2- Breast Cancer

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer (NCT02595905)

Summary

Cisplatin (Platinol®) is a chemotherapy drug used to treat metastatic breast cancer. Researchers want to know if Platinol kills more cancer cells when it is given alone or with other drugs. In this study, researchers will see if Platiniol works better when it is given with veliparib. This drug is a new type of targeted treatment called a PARP inhibitor. To take part in this study, you must have metastatic triple negative (ER-, PR- and HER2-) breast cancer or have an inherited BRCA mutation and metastatic HER2-negative breast cancer.


This is a Phase II trial

Mirvetuximab Soravtansine & Chemotherapy in FRa+ Metastatic Triple Negative Breast Cancer

A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC) (NCT02996825)

Summary

To take part in this study you must have stage IV metastatic breast cancer that is triple negative (ER-, PR- and HER2-) and folate receptor (FR) alpha-positive. You must not have had more than four lines of chemotherapy. This study is testing the safety and effects (good or bad) of a new drug called mirvetuximab soravtansine when it is given with the chemotherapy drug gemcitabine (Gemzar®). Mirvetuximab soravtansine is an antibody drug conjugate (ADC). It uses a drug that targets folate receptors on cancer cells to deliver the chemotherapy drug soravtansine directly to the tumor. Gemzar® is a chemotherapy drug approved to treat metastatic breast cancer. This study also is enrolling patients with other types of FR+ tumors.
This is a Phase I trial

Tecentriq plus Taxol, Herceptin and Perjeta for HER2+ Advanced Breast Cancer

Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (NCT03125928)

Summary

To take part in this study, you must have HER2-positive advanced (some stage III) or metastatic (stage IV) breast cancer. This study will evaluate the safety and effectiveness of adding an immunotherapy to the standard treatment for HER2-positive advanced breast cancer. Atezolizumab (Tecentriq®) is the immunotherapy drug used in this study. It is approved to treat bladder cancer and a type of lung cancer. The standard of care for HER2+ advanced breast cancer treatment is the chemotherapy drug paclitaxel (Taxol®) and the HER2-targeted drugs trastuzumab (Herceptin®) and pertuzumab (Perjeta®).
This is a Phase II trial

Combination of Immunotherapy and Targeted Therapies for HR+ and HER2- Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer) (NCT03280563)

Summary

To take part in this study, you must have HR-positive, HER2-negative advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already been treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor such as palbociclib/Ibrance®, ribociclib/LEE011, or abemaciclib/LY2835219, that your cancer progressed on or did not respond to. This trial is studying 5 different treatment options. Women will receive one, two, or three of the following drugs: the immunotherapy atezolizumab (Tecentriq®), a PD-L1 (programmed cell death-ligand 1) inhibitor approved to treat certain types of bladder and lung cancer; the targeted therapy cobimetinib (Cotellic), which blocks the MEK protein and is approved to treat certain types of melanoma; fulvestrant (Faslodex®), a standard chemotherapy used to treat breast cancer; ipatasertib (GDC-0068), a new type of cancer drug that works by blocking the Akt protein; bevacizumab (Avastin), a monoclonal antibody that keeps tumors from growing the blood vessels they need to survive and is used to treat HER2-negative metastatic breast cancer.


This is a Phase I-II trial

Actimmune with Taxol, Herceptin & Perjeta for HER2+ Breast Cancer

A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer (NCT03112590)

Summary

To take part in this study, you must have HER2-positive breast cancer. If you have advanced (some stage III) or metastatic (stage IV) breast cancer, you are eligible for phase I of this study. If you have stage II-III breast cancer, you are eligible for phase II of this study. This study is evaluating the safety, effects (good and bad) and best dose of Actimmune® (IFN-γ 1b) when it is used along with paclitaxel (Taxol®), trastuzumab (Herceptin®), and pertuzumab (Perjeta®) to treat HER2+ breast cancer. Actimmune is a protein made in the laboratory that is similar to interferon-gamma (IFN-γ), a protein produced by the body's immune cells to prevent infection.
This is a Phase I-II trial

Tecentriq and Paclitaxel for Triple Negative Advanced Breast Cancer

A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT03125902)

Summary

To take part in this study, you must have recently been diagnosed with triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer and not yet started treatment. This study is investigating whether a chemotherapy drug works better when it is given along with an immunotherapy. The chemotherapy drug being used in this study is paclitaxel (Taxol®). It is used to treat breast cancer. The immunotherapy drug being used in this study is atezolizumab (Tecentriq®). It is a PD-L1 inhibitor that is currently approved to treat certain types of bladder and lung cancer.


This is a Phase III trial

Herceptin and Navelbine With Immunotherapy for Advanced HER2+ Breast Cancer

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab (NCT03414658)

Summary

To take part in this study, you must have HER2 positive advanced (stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of three different drug combinations in advanced HER2 positive breast cancer. The drugs being used in this study are: trastuzumab (Herceptin®), vinorelbine (Navelbine®) avelumab (Bevancio®) and utomilumab (PF-05082566). Herceptin is a targeted therapy routinely used to treat HER2-positive breast cancer. Navelbine®) is a chemotherapy drug used to treat HER2-positive breast cancer. Avelumab (Bevancio®) and utomilumab (PF-05082566) are immunotherapies that work by stimulating the body's immune system to go after cancer cells. Both work by blocking a protein called PD-L1. Bevancio is approved to treat metastatic Merkel cell carcinoma and urothelial (bladder) cancers. It's use is considered experimental in breast cancer. Utomilumab is an experimental treatment.


This is a Phase II trial

Carboplatin plus Nivolumab in Advanced Triple Negative Breast Cancer

A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First- or Second-line Metastatic Triple-negative Breast Cancer (NCT03414684)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer. This study is comparing the safety and effects (good and bad) of giving the chemotherapy drug carboplatin (Paraplatin®) alone or with an immunotherapy drug to treat advanced breast cancer. Paraplatin is a chemotherapy drug routinely used to treat advanced breast cancer. The immunotherapy drug used in this study is the PD-1 inhibitor nivolumab (Opdivo®). The drug, which has been approved to treat certain types of cancer, but not breast cancer, stimulates the body's immune system to attack cancer cells by blocking a protein called PD-1 (programmed cell death 1).


This is a Phase II trial

Dinaciclib With Paclitaxel for Advanced Breast Cancer

A Phase I/Ib Dose-escalation Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumor Malignancies and Assessment of MYC Oncogene Overexpression (NCT01676753)

Summary

Scientists are developing new targeted therapies that have the potential to be effective against breast and other solid tumors. Dinaciclib is an investigational drug that inhibits cyclin-dependent kinases (CDKs). Paclitaxel (Taxol ®) is a drug routinely used to treat advanced breast cancer. Combining dinaciclib with Taxol may make cancer cells more likely to respond to Taxol. The purpose of this trial is to collect safety data for the combination of weekly Taxol and dinaciclib in patients with advanced breast cancer (and other types of solid tumors). After the dose is determined, the researchers will expand the trial by enrolling 12 patients with advanced triple-negative breast cancer. The researchers will also try to identify biomarkers that can predict which tumors will respond to dinaciclib.


This is a Phase I trial

Keytruda with Chemotherapy for Treating HER2- Metastatic Breast Cancer

I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC) (NCT03213041)

Summary

To take part in this study, you must have HER2-negative stage IV (metastatic) breast cancer and a blood test that shows you have a circulating tumor cell (CTC) level ≥ 5. This study is investigating the safety and effects (good or bad) of treating HER2-negative metastatic breast cancer with an immunotherapy drug along with a chemotherapy drug. The immunotherapy drug used in this study is pembrolizumab (Keytruda®). It is a type of immunotherapy called a PD-1 inhibitor. The chemotherapy drug is carboplatin (Paraplatin®). It is used to treat metastatic breast cancer.


This is a Phase II trial

Predicting Response to Cisplatin & Radiation in Advanced Triple Negative Breast Cancer

A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy (NCT02422498)

Summary

Researchers are studying the best way to treat triple-negative (ER-, PR-, HER2-) breast cancer. Cisplatin (Platinol®) is a platinum-based chemotherapy drug being studied in patients with triple-negative breast cancer. Radiation therapy can be used to treat cancer cells that have spread to different parts of the body. Researchers have developed a test that they think can be used to predict how well a patient's tumor will respond to concurrent cisplatin and radiation therapy. The test is performed on a biopsy (tissue sample) of the tumor, taken from the breast or elsewhere in the body. In this study, researchers will evaluate how well the test predicts response to cisplatin and radiation therapy in patients with recurrent (stage III) or metastatic (stage IV) triple-negative breast cancer. The biopsy and radiation will be given at Memorial Sloan Kettering Cancer Center.


This is a Phase II trial

Tesetaxel and Capecitabine or Capecitabine Alone For HER2-, HR+ Advanced Breast Cancer

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane (CONTESSA) (NCT03326674)

Summary

To take part in this study, you must have HER2-negative, hormone receptor-positive locally advanced or metastatic breast cancer. For your current diagnosis of locally advanced or metastatic breast cancer, you must have had no more than 1 chemotherapy. You also must have previously been treated with a taxane before being diagnosed with advanced breast cancer. This study is investigating whether using tesetaxel along with a reduced dose of capecitabine is more effective than using capacitabine alone to treat HER2-, HR+ locally advanced or metastatic breast cancer. Tesetaxel is a new type of oral taxane. Capacitabine is an oral chemotherapy drug used to treat breast cancer.
This is a Phase III trial

Keytruda plus Carboplatin to Treat Chest Wall Breast Cancer

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease (NCT03095352)

Summary

To take part in this study, you must have locally recurrent (some stage III) or metastatic (stage IV) breast cancer that has spread to the chest wall and cannot be removed by surgery. This study is comparing the safety and effects (good and bad) of giving immunotherapy along with chemotherapy to giving chemotherapy and a placebo to treat breast cancer that has spread to the chest wall. Pembrolizumab (Keytruda®) is the immunotherapy drug used in this study. It is a PDL-1 inhibitor approved to treat certain types of cancers. Carboplatin (Paraplatin®) is the chemotherapy drug used in this study. In this trial, researchers will test tumor biopsies and blood samples before and after treatment in order to learn more about how genes and the immune system affect how tumors respond to immunotherapy.


This is a Phase II trial

ABBV-155 for Advanced Breast (and Other) Cancers

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors (NCT03595059)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer.

This study will evaluate the safety of a new cancer drug, determine the best dose of the drug to use, and look at the effects (good and bad) of the best dose.The experimental drug is called ABBV-155. It is only available in clinical trials. ABBV-155 will be given with paclitaxel (Taxol®) a drug approved to treat breast cancer. This study is also enrolling patients with other types of cancer.


This is a Phase I trial

Tecentriq & Targeted Therapy or Chemotherapy for Metastatic Triple Negative Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC) (NCT03424005)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer that progressed during or following first-line metastatic treatment with chemotherapy. This study is investigating the safety and effectiveness of 7 different immunotherapy-based treatment combinations in women and men with triple negative (ER-/PR-/HER2-) breast cancer. The immunotherapy being used in this study is atezolizumab (Tecentriq®). It is a PD-L1 inhibitor that works by stimulating the body's immune system to go after cancer cells. It is approved to treat certain types of urinary, bladder and lung cancer. The targeted therapies being used in the study are Ipatasertib (GDC-0068), SGN-LIV1A, bevacizumab (Avastin®) and cobimetinib (Cotellic®). The chemotherapies being used in this study are capecitabine (Xeloda®), gemcitabine (Gemzar®), carboplatin (Paraplatin®) and eribulin (Halaven®).


This is a Phase I-II trial

Methotrexate in Patients With Metastatic Breast Cancer and Leptomeningeal Metastasis

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail (NCT02422641)

Summary

To take part in this study you must have metastatic breast cancer with leptomeningeal metastases.

This study is evaluating the effects (good and bad) of using high-dose methotrexate to treat metastases that shows up in the cerebrospinal fluid surrounding the brain and spinal cord and/or in the leptomeninges, the lining of the brain and spinal cord. This type of metastasis is called leptomeningeal disease. Methotrexate is a chemotherapy drug approved to treat advanced breast cancer. Researchers believe methotrexate can cross the blood-brain barrier to be effective in patients with leptomeningeal metastases.


This is a Phase II trial

A New Targeted Therapy and Taxol for Advanced Breast Cancer

A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer (NCT02776917)

Summary

To take part in this study, you must have triple negative (ER-, PR-, or HER2-) or hormone receptor positive (ER+ or PR+), advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good and bad) of a new type of targeted therapy when it is given along with the chemotherapy drug paclitaxel (Taxol®) to treat advanced breast cancer. The experimental targeted therapy is cirmtuzumab. It blocks proteins found only on cancer cells. Taxol is commonly used to treat breast cancer.
This is a Phase I trial

Using Personalized T-Cells Along with Chemotherapy to Treat Metastatic Breast Cancer

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer (NCT03412877)

Summary

To take a part in this study, you must have metastatic (stage IV) breast cancer for which standard treatments have not worked.

This study is investigating the safety and effects (good or bad) of an immunotherapy that uses personalized T cells. To create the personalized T cells, cancer cells will be taken from your tumor and white blood cells will be removed from your blood. The cancer cells will be analyzed to learn about the genetic mutations they contain. In a lab, your white blood cells will be modified in ways that will help them go after your tumor cells. They will then be infused into your body. This will take place in the hospital where the research study is taking place. When you receive the infused T cells, you will also be given Aldesleukin, an immune function enhancing drug. Your treatment will also include two chemotherapy drugs: cyclophosphamide (Cytoxan), which is used to treat breast cancer, and fludarabine (Fludara), which is approved to treat chronic lymphocytic leukemia (CLL). This trial also is enrolling patients with other types of metastatic cancer.


This is a Phase II trial

Triciribine & Paclitaxel in Stage II-III HER2 Negative Tumors

A Phase I-II Study of Triciribine Phosphate Monohydrate (TCN-PM) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer (NCT01697293)

Summary

Researchers are studying new drugs and new drug combinations for treating locally advanced breast cancer. Triciribine Phosphate Monohydrate (TCN-PM) is a type of new cancer drug called an AKT inhibitor. AKT is a protein that plays a role in cell growth and cell death. In cancer cells, this protein is not working properly, which helps the tumor grow and spread. The researchers think that giving TCN-PM along with the chemotherapy drug paclitaxel (followed later in time by additional chemotherapy) may be more effective than paclitaxel alone. This study is looking at the affect that giving TCN-PM along with paclitaxel has on HER2-negative locally advanced breast tumors. The first phase of this trial will also enroll patients with stage IV (metastatic) breast cancer.


This is a Phase I-II trial

Targeted therapy followed by Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer (NCT03193853)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) metastatic (stage IV) breast cancer. Your tumor must also test negative for androgen receptors. In addition, you must have already had chemotherapy (anthracycline, cyclophosphamide, and taxane). This study is investigating the safety and effects (good or bad) of using two targeted drugs followed by chemotherapy to treat triple negative metastatic breast cancer. The targeted drugs used in this study are TAK-228 and TAK-117. Both are mTOR inhibitors. Cisplatin (Paraplatin®) and nab-paclitaxel (Abraxane®) are the chemotherapy drugs used in this study.


This is a Phase II trial

BGB-290 with Temozolomide for Advanced Breast (and Other) Cancer

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03150810)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. This study will investigate the safety and effects (good or bad) of using an oral chemotherapy along with a new targeted drug to treat advanced breast cancer. The two drugs being used in this study are temozolomide (Temodar) and BGB-290. Temodar is used to treat brain cancer. BGB-290 is a type of targeted therapy called a PARP inhibitor.


This is a Phase I-II trial

Adding Neratinib to Treatment Regimens for Advanced or Inflammatory Breast Cancer

A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC (NCT03101748)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. If you have inflammatory breast cancer, your tumor must be ER-positive to be eligible for this study. This study is investigating the safety and best dose of neratinib (Nerlynx®) to add to drug regimens used to treat advanced breast cancer. Neratinib is a tyrosine kinase inhibitor approved for use in patients with early-stage HER2-positive breast cancer who have already received trastuzumab (Herceptin®). The HER2-targeted drugs used in this study are pertuzumab (Perjeta®) and Herceptin. The chemotherapy drugs used in this study are doxorubicin/Adriamicin® and cyclophosphamide/Cytoxan®. Your treatment regimen will be determined by whether your tumor is HER2+ or HER2- and if you have inflammatory breast cancer. Women with inflammatory breast cancer will also have surgery.
This is a Phase I-II trial

Carboplatin plus Atezolizumab for Metastatic Triple Negative Breast Cancer

A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer (NCT03206203)

Summary

To take part in this study, you must have metastatic (stage IV), triple negative (ER-/PR-/HER2-) breast cancer. This study is investigating whether using a combination of immunotherapy and chemotherapy is better than using chemotherapy alone to treat triple negative metastatic breast cancer. Carboplatin (Paraplatin®) is the chemotherapy drug used in this study. Atezolizumab (Tecentriq®) is the immunotherapy drug used in this study.


This is a Phase II trial

Atezolizumab plus Chemotherapy for Early Relapsing Recurrent Triple Negative Breast Cancer

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer (NCT03371017)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer. This study is evaluating the safety and effects (good or bad) of giving chemotherapy with an immunotherapy to giving chemotherapy with a placebo. The immunotherapy drug being used in this study is atezolizumab (Tecentriq®). The chemotherapy drugs used in this study are gemcitabine (Gemzar®), carboplatin (Paraplatin®) and capecitabine (Xeloda®). Gemzar is a chemotherapy drug used to treat breast cancer. Paraplatin is a platinum-based chemotherapy drug that is commonly used to treat triple negative breast cancer. Xeloda is commonly used to treat metastatic breast cancer.


This is a Phase III trial

MCLA-128, Herceptin & Chemo or Hormone Therapy for HER2+ or ER+/Low HER2 Breast Cancer

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC (NCT03321981)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and a tumor that is HER2-positive or ER-positive with low HER2-expression. This study is evaluating the effects (good or bad) of an experimental immunotherapy drug called MCLA-128. If your tumor is HER2+, you will receive MCLA-128 along with the HER2-targeted drug trastuzumab (Herceptin®). If you are ER+, you will receive MCLA-128 along with the same endocrine therapy you received before entering the study: fulvestrant (Faslodex®), exemestane (Aromasin®), letrozole (Femara®) or anastrozole (Arimidex®). The chemotherapy drug used in this study is vinorelbine (Navelbine®).
This is a Phase II trial

Kadcyla and Temodar for Recurrent HER2+ Brain Metastases from Breast Cancer

Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery (NCT03190967)

Summary

To take part in this study, you must have HER2-positive breast cancer and have brain mets that have returned after treatment with radiation and/or surgery. The brain mets must have been treated with stereotactic radiation or surgery within 6 weeks of starting treatment on the trial. This study is investigating the safety and effects (good and bad) of using a targeted therapy along with chemotherapy to treat HER2-positive breast cancer that has spread (metastasized) to the brain. The targeted therapy used in this study is T-DM1 (Kadcyla®). It is used to treat HER2-positive metastatic breast cancer. It combines the chemotherapy drug DM1 with the HER2-targeted drug trastuzumab (Herceptin®). The chemotherapy drug used in this study is temozolomide (Temodar®). It is used to treat brain cancer. If you participate in this study you will have at least two lumbar punctures (spinal taps). During this procedure, a needle is inserted into the spinal canal in the lower back to collect cerebrospinal fluid. You will receive local anesthesia and imaging will be used to guide the procedure.


This is a Phase I-II trial

HSP90 Inhibitor and Taxol for Advanced Triple Negative Breast Cancer

Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer(NCT02474173)

Summary

To take part, you must have some stage III-IV triple negative (ER-/PR-/HER2-negative) breast cancer. Researchers have developed a new type of drug called an HSP90 inhibitor. The HSP90 inhibitor being used in this study is named AT13387. This study is investigating whether AT13387 helps kill cancer cells and what side effects women experience when they are given it along with paclitaxel (Taxol®). AT13387 is a new drug that is only available in clinical trials. Taxol is a chemotherapy drug used to treat breast cancer.


This is a Phase I trial

Neratinib and Xeloda for Metastatic HER2+ Breast Cancer

Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer (NCT03377387)

Summary

To take part in this study, you must have HER2-positive metastatic (stage IV) breast cancer. This study is investigating the safety and effect (good or bad) of using a targeted therapy in combination with different doses of a standard chemotherapy. The targeted therapy that is being used in this study is neratinib (Nerlynx®). It is approved to treat certain patients with HER2+ early-stage breast cancer. Capacitabine (Xeloda®) is approved by the FDA for treating advanced breast cancer.
This is a Phase I-II trial

CORT125134 and Abraxane for Advanced Breast Cancer

Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors (NCT02762981)

Summary

To take part in this study, you must be have stage III or stage IV breast cancer. This study is investigating the safety and effectiveness of using the approved breast cancer drug nab-paclitaxel (Abraxane®) along with a new drug called CORT125134. The new drug, CORT125134, is a type of drug called a glucocorticoid receptor antagonist. It is available only in clinical trials.


This is a Phase I-II trial

Keytruda plus Two Chemotherapy Drugs for Metastatic Triple-Negative Breast Cancer

Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer (NCT03121352)

Summary

To take part in this study, you must have metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer. You cannot have had more than two prior therapies for your metastatic diagnosis. This study will determine the effectiveness of giving two chemotherapy drugs along with an immunotherapy drug. The immunotherapy drug used in this study is pembrolizumab (Keytruda®). It is approved to treat some types of metastatic cancer. Carboplatin (Paraplatin®) and nab-paclitaxel (Abraxane®) are chemotherapy drugs routinely used to treat advanced breast cancer.


This is a Phase II trial

Tecentriq and Stereotactic Radiosurgery for Triple Negative Breast Cancer Brain Mets

A Phase II Study of Atezolizumab in Combination With Stereotactic Radiosurgery for Patients With Triple-negative Breast Cancer and Brain Metastasis (NCT03483012)

Summary

To take part in this study, you must have metastatic (stage IV), triple negative (ER-/PR-/HER2-) breast cancer that has spread to the brain. This study is investigating the effectiveness of treating breast cancer brain metastases with stereotactic radiosurgery and an immunotherapy drug. Stereotactic radiosurgery delivers focused radiation to each individual brain metastasis. It is routinely used to treat brain metastases. The immunotherapy drug being used in this study is atezolizumab (Tecentriq®) It gets the immune system to go after cancer cells by blocking a protein called PD-L1 (programmed cell death-ligand 1). It is approved to treat certain types of bladder cancer and lung cancer.


This is a Phase II trial

Hypofractionated Radiation Therapy with MEDI4736 & Tremelimumab for Metastatic Cancer

Phase I Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers (NCT02639026)

Summary

Hypofractionated radiation therapy involves giving larger doses of radiation in fewer sessions over a shorter period of time. MEDI4736 and tremelimumab are two different types of immunotherapy drugs. MEDI4736 blocks the PD-1 (programmed cell death-1) protein. Blocking this protein makes it possible for the immune system to go after cancer cells. Tremelimumab blocks the CTLA-4 protein, which also keeps the immune system from attacking cancer cells. This study is comparing the safety and the effectiveness of two different hypofractionated radiation therapy schedules when used along with MEDI4736 and tremelimumab to treat metastatic breast (and other) tumors.


This is a Phase I trial

SBRT Radiation Therapy for Patients With Oligoprogressive Metastatic Breast Cancer

A Randomized Phase II Study Assessing the Efficacy of Local Ablative Radiation Therapy for Metastatic Breast and Lung Cancer Patients With Oligoprogressive Disease (NCT03808662)

Summary

To take part in this study you must have oligoprogessive metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has progressed on at least one other systemic treatment.

Patients with oligoprogressive metastatic breast cancer have a small number of metastatic tumors in one or two other parts of the body. This study will compare the safety and effects (good or bad) of using stereotactic body radiation therapy (SBRT) to treat each site of metastases followed by a standard of care treatment to a standard of care treatment alone. SBRT uses multiple radiation beams to deliver high doses of precision radiation directly to the tumor.


This is a Phase II trial

  • Participation Time1 visit every other day for 6 or 10 days, then coincides with standard treatment
  • Participating research sites
    Research sites: 8 sites total

Immunotherapy and Radiation Therapy for ER+ HER2- Metastatic Breast Cancer

RACHEL1: A Phase I Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03524170)

Summary

To take part in this study, you must be a woman or man with estrogen receptor positive and HER2 negative metastatic (stage IV) breast cancer.

This study will help determine the best dose, safety and effects (good and bad) of an investigational immunotherapy drug called M7824 when used along with radiation therapy to treat patients with ER positive, HER2 negative metastatic breast cancer.


This is a Phase I trial

Focused Ultrasound and Pembrolizumab in Advanced Breast Cancer

Focused Ultrasound Therapy to Augment Antigen Presentation and Immune-Specificity of Checkpoint Inhibitor Therapy With Pembrolizumab in Metastatic Breast Cancer (NCT03237572)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have had at least one prior line of therapy in the metastatic setting. This study will evaluate the safety and effects (good and bad) of using high-intensity focused ultrasound (HIFU) along with Keytruda to treat metastatic breast cancer. HIFU is a treatment that works to kill cancer cells with high frequency sound waves. Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It stimulates the body's immune system to go after cancer cells.


This is a Phase I trial

Stereotactic Body Radiation Therapy for Breast Cancer with Limited Metastasis

A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (NCT02364557)

Summary

When breast cancer spreads to only one or two locations in the body, it is referred to as limited metastatic (oligometastatic) breast cancer. Stereotactic body radiation therapy (SBRT) delivers a high dose of radiation directly to the tumor, reducing the risk of damaging surrounding healthy tissue. Researchers think SRBT may be a promising treatment for women with limited metastases. This study is comparing the effectiveness of using SRBT along with systemic therapy to systemic therapy alone for treating women with newly diagnosed and limited metastases.


This is a Phase II-III trial

Comparing Two Methods for Evaluating Brain Mets After Radiation

Pilot Study of 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain (NCT01621906)

Summary

Researchers are trying to develop better methods for evaluating how brain metastases respond to whole brain radiation therapy (WBRT). This study is comparing a positron emission tomography (PET) scanner with a magnetic resonance imaging (MRI) scanner. A PET scanner resembles a CT or MRI scanner. PET scans use radioactive substances, called radioactive markers, to "see" cancer cells. This study will use [18F]FLT as the radioactive marker. FLT is used to image tumor growth. FLT PET scan is a new clinical procedure. (It differs from FDG-PET, which is more commonly used.) This study will help researchers determine whether the FLT PET scan is safe and more effective for evaluating brain metastases than MRI. To be eligible participants must be planning on receiving WBRT.

Radiation & A New Immunotherapy Before Pembrolizumab for Advanced Triple Negative Disease

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab (STOMP) (NCT03004183)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-), advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effect (good and bad) of using stereotactic body radiation therapy, a vaccine and an immunotherapy to treat advanced triple negative breast cancer. Stereotactic body radiation therapy (SBRT) delivers a high dose of radiation directly to the tumor. The vaccine is called ADV/HSV-tk. It is given along with the anti-viral drug valacyclovir. The immunotherapy used in this study is pembrolizumab (Keytruda®). It is approved to treat certain types of cancers. This study is also recruiting patients with advanced non-small cell lung cancer.


This is a Phase II trial

Study of Radiation Techniques to Treat Patients With 5 to 15 Brain Metastases

Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-15 Brain Metastases: A Phase III, Randomized Clinical Trial (NCT03075072)

Summary

To take part in this study, you must have metastatic (stage IV) breast cancer and have between 5 and 15 brain metastases. This study is investigating whether patients with brain metastases who receive stereotactic radiation have fewer side effects and a better quality of life than those who receive whole brain radiation. Stereotactic radiation delivers focused radiation to each individual brain metastasis. Whole brain radiation treats the entire brain. This study is also open to patients with other types of cancer.


This is a Phase III trial

G1T48 for Advanced ER+ HER2- Breast Cancer

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (NCT03455270)

Summary

To take part in this study you must have ER positive, HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer and have been treated with an aromatase inhibitor.

This study will evaluate the safety and effects (good and bad) of a using the hormonal therapy G1T48 to treat ER positive, HER2 negative advanced or metastatic breast cancer. G1T48 is type of hormone therapy called a selective estrogen receptor degrader (SERD).


This is a Phase I trial

Estrogen and an Aromatase Inhibitor in Advanced ER+ Breast Cancer

Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Advanced Breast Cancer (NCT02188745)

Summary

Anti-estrogen therapies are used to treat ER+ tumors. However, over time, these tumors can stop responding to these treatments. Laboratory studies suggest that giving a high dose of estrogen to patients whose tumors have stopped responding to an anti-estrogen therapy may get the tumor to respond again to the treatment. This study will investigate how tumors respond when estrogen (17B-estradiol) is given along with an aromatase inhibitor––letrozole (Femara®), anastrozole (Arimidex®) or exemestane (Aromasin®) to treat women with advanced ER+, HER2- metastatic breast cancer. To be eligible for this study, a patient must have been previously treated with tamoxifen, raloxifene, toremifene, or an AI.
This is a Phase II trial

H3B-6545 for Postmenopausal Women with ER+, HER2- Breast Cancer

A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer (NCT03250676)

Summary

To take part in this study, you must be a postmenopausal woman who has ER+, HER2- advanced (some stage III) or metastatic (stage IV) breast cancer that progressed on your most recent therapy. This study will determine the best dose, safety, and effects (good and bad) of an experimental anti-estrogen drug called H3B-6545.
This is a Phase I-II trial

RAD140 for Postmenopausal Women With HR+ Advanced Breast Cancer

A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer (NCT03088527)

Summary

To take part in this study, you must be postmenopausal and have HR-positive advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety, best dose, and effects (good or bad) of an investigational hormone therapy called RAD140 in patients whose tumors are no longer responding to standard treatme


This is a Phase I trial

Faslodex or Tamoxifen for ER-Positive Metastatic Breast Cancer

Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen: A Randomized Phase II Trial With ESR1 Mutation Tested in Circulating Tumor DNA (NCT02913430)

Summary

To take part in this study, you must have ER-positive metastatic breast cancer. You must also have not been treated with Faslodex or tamoxifen since being diagnosed with metastatic breast cancer. This study is comparing how well two different anti-estrogen drugs keep metastatic breast cancer from spreading. The two drugs are fulvestrant (Faslodex®) and tamoxifen (Nolvadex®). Both are used to treat metastatic breast cancer. The researchers will use blood tests to study each patient's circulating tumor DNA—DNA from the cancer that floats in the blood stream—in order to learn more about a mutation called ESR1 and why hormone-sensitive tumors stop responding to anti-estrogen treatments.


This is a Phase II trial

D-0502 Alone or in Combination With Ibrance in ER+, HER2- Advanced Breast Cancer

A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer (NCT03471663)

Summary

To take part in this study, you must have ER positive, HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety, effects (good and bad) and best dose of an experimental anti-estrogen therapy when it is given alone or in combination with palbociclib (Ibrance®). D-0502 is the experimental anti-estrogen therapy used in this study. Ibrance®) is approved to treat hormone sensitive, HER2 negative breast cancer in combination with an anti-estrogen therapy in postmenopausal women. If you are premenopausal, you will also be given a therapy that will stop your ovaries from producing estrogen.


This is a Phase I trial

Sunitinib for Metastatic HER2+ Breast Cancer That Has Progressed on HER2+ Therapies

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy (NCT02500199)

Summary

Researchers are studying new ways to treat metastatic HER2+ breast cancer that has stopped responding to HER2-targeted therapies. Pyrotinib, a tyrosine kinase inhibitor, is an experimental targeted therapy. It targets both HER1 and HER2. In this study, researchers are investigating the safety, effectiveness and the best dose of pyrotinib to treat HER2+ metastatic breast cancer that has stopped responding to other HER2-targeted therapies. To be eligible, participants must have had their cancer progress after having been on at least two prior HER2-targeted therapies, including trastuzumab (Herceptin®) and/or pertuzumab (Perjeta®), or T-DM1 (Kadcyla®), or lapatinib (Tykerb®).
This is a Phase I trial

TAK-228 and Letrozole in Postmenopausal Women With High-Risk ER+ and HER2-Low Breast Cancer

Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer (NCT02619669)

Summary

To take part in this study you must be a postmenopausal woman with stage I, stage II, stage III or metastatic (stage IV) breast cancer that is estrogen receptor (ER) positive and low HER2 (defined as IHC 0-1+) and has a high risk for recurrence. This study is investigating the safety and effects (good or bad) of the combination of TAK-228 and letrozole (Femara®) when given before surgery. This is called neoadjuvant treatment. TAK-228 is a new type of targeted therapy called a TORC inhibitor. Femara® is a type of hormone therapy called an aromatase inhibitor. It is approved to treat postmenopausal women with breast cancer.
This is a Phase I trial

Targeted Therapy Rebastinib With Carboplatin for Advanced Breast Cancer

An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors (NCT03717415)

Summary

To take part in this study you must have advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.

This study is investigating the safety, dose and effects (good and bad) of the targeted therapy rebastinib (DCC-2036) when used along with carboplatin (Paraplatin®). Rebastinib targets a receptor called TIE2. Researchers believe blocking this protein will keep tumors from growing and spreading. Paraplatin is a chemotherapy drug routinely used to treat advanced and metastatic triple negative breast cancer.


This is a Phase I-II trial

Copanlisib, Letrozole, and Ibrance for HR+, HER2- Stage I-IV Breast Cancer

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors (NCT03128619)

Summary

To take part in this study, you must have ER+, HER2- early stage (stage I-III) or metastatic (stage IV) breast cancer. This trial has two phases. In phase one, researchers will determine the safety and best dose of the drug capanlisib when it is given with Femara to treat advanced (some stage III and IV) breast cancer. In phase two, researchers will compare the safety and effect of giving combinations of targeted therapies with a hormone therapy. Palbociclib (Ibrance®) and copanlisib are the targeted therapies used in this study. Ibrance targets the CDK4/6 protein. It is approved by the FDA to treat postmenopausal women with ER+, HER2- metastatic breast cancer. Copanlisib targets the PI3K protein. Copanlisib is approved to treat a certain type of blood cancer. Letrozole (Femara®) is the hormone therapy used in this study. It is approved to treat hormone-sensitive breast cancer
This is a Phase I-II trial

Talazoparib for HER2-Negative Advanced Breast Cancer

A Phase II Clinical Trial of BMN 673 in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency as Assessed by the HRD Assay, and (ii) Advanced HER2-Negative Breast Cancer With Either a Germline or Somatic Mutation in... (NCT02401347)

Summary

Talazoparib (BMN 673) is a PARP inhibitor. Studies suggest PARP inhibitors may be effective in some types of breast cancer. Early studies suggest talazoparib may be effective in cancer patients who have an inherited BRCA1/2 mutation. It may also be effective in patients who do not have a BRCA1/2 mutation. This study is investigating the safety and effectiveness of talazoparib in patients with HER2-negative advanced breast cancer who do not have a BRCA1/2 mutation. To be eligible, participants must have advanced triple negative breast cancer or HER2-negative breast cancer with a mutation in another gene. Participants will have their tumor tested for genetic mutations to determine eligibility.


This is a Phase II trial

Faslodex, Ibrance & Erdafitinib for ER+, HER2-, Advanced Breast Cancer

A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC) (NCT03238196)

Summary

To take part in this study, you must have ER+, HER2- metastatic (stage IV) breast cancer. Your tumor will be tested to see if it is FGFR-amplified. It must be FGFR-amplified for you to take part in this study. This study is investigating the best dose, safety and effects (good or bad) of giving targeted therapies along with hormone therapy. Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. Erdafitinib (JNJ-42756493) is an experimental targeted therapy that works by targeting the FGFR tyrosine kinase protein. Fulvestrant (Faslodex®) is the hormone therapy used in this study. It is approved to treat metastatic breast cancer.
This is a Phase I trial

Tecentriq, Cotellic & Halaven for Metastatic Inflammatory Breast Cancer

A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (NCT03202316)

Summary

To take part in this study, you must have inflammatory advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already been treated with a chemotherapy that your cancer progressed on or did not respond to. In this study, researchers will determine the safety and effect (good or bad) of using a combination of immunotherapy, targeted therapy and chemotherapy to control metastatic inflammatory breast cancer. Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. It is FDA approved to treat certain types of bladder and lung cancer. Cobimetinib (Cotellic®) is a new targeted therapy called an MEK inhibitor. It is approved to treat certain types of melanoma. Eribulin (Halaven®) is a chemotherapy drug approved for treating metastatic breast cancer.


This is a Phase II trial

DHES0815A for Advanced HER2-Positive Breast Cancer

A Phase I, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of DHES0815A in Patients With HER2-Positive Breast Cancer (NCT03451162)

Summary

To take part in this study, you must have HER2-positive, advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already received a treatment that your cancer progressed on or did not respond to.

In this study, researchers will evaluate the safety, best dose, and effects (good and bad) of an experimental therapy called DHES0815A for treating HER2-positive metastatic breast cancer. DHES0815A is an antibody-drug conjugate (ADC). It combines chemotherapy with a HER2 targeted therapy, allowing it to deliver the chemotherapy directly to the cancer cells.


This is a Phase I trial

Mirvetuximab Soravtansine for Triple Negative Breast Cancer

Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC(NCT03106077)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) breast cancer. You must also have a tumor that express folate receptor alpha (FRα). Researchers will test your tumor for this receptor. This study will determine the safety and effects (good and bad) of using an experimental drug that targets FRα to treat early-stage or metastatic triple negative breast cancer. Studies suggest FRα helps tumors grow and spread. The experimental drug used is called mirvetuximab soravtansine (IMGN853).


This is a Phase II trial

Lynparza and Onalespib for Metastatic Triple Negative Breast Cancer

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer (NCT02898207)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) metastatic (stage IV) breast cancer. This study will determine the safety and best dose of two targeted drugs for treating metastatic breast cancer. The two targeted drugs being used in this study are olaparib (Lynparza®) and onalespib (AT13387). Lynparza is a PARP inhibitor. It is approved by the FDA to treat ovarian cancer. Onalespib is an experimental HSP90 inhibitor. This trial is also enrolling patients with other types of cancers.


This is a Phase I trial

AB-ROR2-ADC for Advanced Breast Cancer

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors (NCT03504488)

Summary

To take part in this study you must have advanced (some stage III) or metastatic (stage IV) breast cancer that has not responded to standard therapies.

This study is investigating the safety and effects (good or bad) of an experimental drug called CAB-ROR2-ADC (BA3021). CAB-ROR2-ADC is a type of drug called an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells. The antibody in this drug targets ROR2 proteins. This study is also enrolling patients with other types of advanced cancer.


This is a Phase I-II trial

Margetuximab or Trastuzumab with Chemotherapy for HER2+ Advanced Breast Cancer

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment (SOPHIA) (NCT02492711)

Summary

Trastuzumab (Herceptin®) is a targeted therapy routinely used to treat HER2-positive breast cancer. MAGH22 (Margetuximab) is a new HER2-targeted therapy. This study is comparing the effectiveness of Margetuximab and chemotherapy to Herceptin and chemotherapy in patients with HER2-positive advanced breast cancer. The patient's physician will choose the chemotherapy regimen.


This is a Phase III trial

SGN-LIV1A and Keytruda for Advanced Triple Negative Breast Cancer

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (NCT03310957)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer. This study is looking at the safety and effects (good or bad) of using SGN-LIV1A along with pembrolizumab (Keytruda®) to treat triple negative advanced or metastatic breast cancer. SGN-LIV1A is an investigational drug that targets a protein called LIV-1 that is found on some tumor cells. Keytruda® is a type of immunotherapy drug called a PD-1 inhibitor. It blocks the PD-1 (programmed cell death-1) protein, making it possible for the body's immune system to go after cancer cells. Keytruda is not approved to treat breast cancer. It is approved to treat certain other types of cancer.


This is a Phase I-II trial

Avelumab Plus Talazoparib to Treat Advanced Breast Cancer

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors (NCT03330405)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) or HR+, locally advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of using an immunotherapy along with a targeted therapy to treat advanced breast cancer. The immunotherapy being used in this study is abelumab (Bavencio®). It works by blocking a protein called PD-L1 (programmed cell death-ligand 1). Talazoparib (BMN-637) is a type of targeted therapy called a PARP inhibitor. It prevents the PARP protein from repairing damaged DNA in tumor cells. This study is also enrolling patients with other types of solid tumors.
This is a Phase II trial

Merestinib for Breast Cancer with Bone Metastases

An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer (NCT03292536)

Summary

To take part in this study, you must have metastatic (stage IV) breast cancer that has spread to the bone. This study will determine the safety and effects (good and bad) of using merestinib to treat bone metastasis. Merestinib (LY2801653) is a new type of targeted therapy called a c-met inhibitor.


This is a Phase I trial

Herceptin for HER2-Positive Breast Cancer That Has Spread to the Brain

Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer (NCT02571530)

Summary

Trastuzumab (Herceptin®) is used to treat HER2-positive breast cancer. It is delivered intravenously. However, the blood-brain barrier prevents much of the drug from getting to cancer cells that have spread to the brain. This study is evaluating the safety of administering a single dose of trastuzumab into an artery in the brain to treat HER2+ brain metastases.
This is a Phase I trial

Basket Study of Entrectinib in Tumors With a NTRK1/2/3, ROS1, or ALK Mutation

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (NCT02568267)

Summary

Basket studies enroll patients based on the kind of mutations found in their tumors, rather than the type of cancer they have. This is a basket study of entrectinib (RXDX-101) in individuals with solid tumors that have an NTRK1/2/3, ROS1, or ALK gene rearrangement. To be eligible, a breast cancer patient must have a tumor that tests positive for a NTRK1/2/3, ROS1 or ALK rearrangement.


This is a Phase II trial

Gedatolisib plus PTK7-ADC for Metastatic Triple Negative Breast Cancer

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer (NCT03243331)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) metastatic (stage IV) breast cancer.

This study is investigating the safety and effects (good or bad) of using two investigational drugs to treat metastatic triple negative breast cancer. The two drugs are gedatolisib and PTK7-ADC. Gedatolisib is a targeted therapy that works by blocking PI3K and mTOR kinase proteins, which play a role in the cellular pathways that help tumors grow. PTK7-ADC (PF-06647020) targets a protein called PTK7, which is often found on cancer cells. It is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a drug that can kill these cells.


This is a Phase I trial

PF-05212384 + Other Drugs for Advanced ER+, HER2+ or Triple Negative Breast Cancer

A Phase 1B Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (PI3K/MTor Inhibitor) In Combination With Other Anti-Tumor Agents (NCT01920061)

Summary

Researchers are studying new drug combinations that could be used to treat advanced breast cancer. PKI-587 (PF-05212384) is a type of targeted therapy called an PI3K/mTOR inhibitor. It prevents cancer cells from growing by blocking PI3K and mTOR proteins. Docetaxel (Taxotere®) and cisplatin (Platinol®) are chemotherapy drugs that are routinely used to treat advanced breast cancer. Dacomitinib is a new type of HER2-targeted therapy that is currently being studied in clinical trials. This study is looking at the safety and effectiveness of using taxotere and PF-05212384 to treat advanced ER+ breast cancer; platinol and PF-05212384 to treat advanced triple negative breast cancer, and dacomitinb and PF-05212384 to treat advanced HER2+ breast cancer.
This is a Phase I trial

NCI-MATCH: Choosing the Best Drug for Metastatic Breast (and Other) Cancer

A Basket study: Molecular Analysis for Therapy Choice (MATCH) (NCT02465060)

Summary

Cancer cells grow because they have genetic mistakes (mutations) inside them. Scientists are developing cancer treatments that keep these mistakes from helping the cancer grow. The National Cancer Institute (NCI) started a trial called MATCH (Molecular Analysis for Therapy Choice). If you enroll in NCI-MATCH, the researchers will test your tumor (that's what they mean by molecular analysis) to see what genetic mistakes it contains. The researchers will then see if there is a cancer drug that is a good match for your tumor's genetic mistakes (that's what they mean by therapy choice). To take part in this study, you must have already had one treatment since learning you have metastatic breast cancer.


This is a Phase II trial

GEN1029 for Advanced Breast (and Other) Cancer

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors (NCT03576131)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already been treated with standard treatments or have no standard treatment available.

In this study, researchers will determine the best dose and effects (good and bad) of a new type of targeted cancer therapy called GEN1029 (HexaBody®-DR5/DR5). Patients with other types of cancers will also be enrolled in this study.


This is a Phase I-II trial

Ibrance & Casodex for Metastatic Triple Negative Breast Cancer with Androgen Receptors

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (NCT02605486)

Summary

Palbociclib (Ibrance®) is a targeted therapy that keeps cancer cells from growing by blocking two enzymes, CDK 4 and CDK 6. It is used to treat metastatic breast cancer. Bicalutamide (Casodex®) is an anti-androgen drug used to treat prostate cancer. Some breast cancers contain androgen receptors. Laboratory studies suggest these tumors may respond to anti-androgen treatment. This study is testing the safety and effectiveness of using Ibrance and Casodex to treat triple negative breast cancer that is androgen receptor positive. To be eligible for this trial, participants must have triple negative, androgen receptor positive, metastatic breast cancer.


This is a Phase I-II trial

Radiation With or Without Tykerb® for HER2+ Brain Metastases

Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer (NCT01622868)

Summary

Whole-brain radiotherapy is the most frequently used therapy for breast cancer brain metastases. This is because most chemotherapy drugs are not able to cross the blood-brain barrier. Lapatinib (Tykerb®) is a kinase inhibitor that targets HER2 as well as the epidermal growth factor receptor (EGFR). It is used with capecitabine (Xeloda®) to treat advanced HER2+ breast cancer in people who have already been treated with other chemotherapy drugs. It is unclear whether Tykerb is able to cross the blood-brain barrier. The purpose of this trial is to determine if whole-brain radiotherapy given along with Tykerb is more effective than whole-brain radiotherapy given alone.
This is a Phase II trial

Entinostat, Opdivo and Yervoy in Advanced HER2-Negative Breast Cancer

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors (NCT02453620)

Summary

Entinostat is a histone deacetylase (HDAC) inhibitor. It is designed to block HDAC enzymes, which are needed for cell growth. Nivolumab (Opdivo®) is an immunotherapy that blocks a protein called PD-1 (programmed cell death 1). Blocking PD-1 may allow the body’s own immune cells to attack cancer cells. It is approved for advanced lung cancer. Ipilimumab (Yervoy®) is an immunotherapy that stimulates T-cells in the body’s immune system. It is approved for treating patients with advanced melanoma. This trial is designed to identify the side effects and best dose of entinostat and Opdivo when the two drugs are given with Yervoy to treat advanced HER2-negative breast cancer.


This is a Phase I trial

Immunotherapy Plus a Targeted Drug for Advanced Triple Negative Breast Cancer

Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589) (NCT02890069)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer. You must also have already received a treatment that your cancer progressed on or did not respond to. This study is looking at whether a new immunotherapy drug is safe and effective when given along with a targeted drug to patients with advanced or metastatic triple negative breast cancer. The immunotherapy drug used in this study is called PDR001. You will receive one of three targeted drugs: LCL161, everolimus (Afinitor®), or panobinostat (LBH589). This study is also enrolling patients with other types of cancer.


This is a Phase I trial

A HER2-Targeted Drug for Advanced HER2-Positive Breast Cancer

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers (NCT02892123)

Summary

To take part in this study, you must have stage III or stage IV (metastatic) HER2-positive breast cancer and have already received at least one treatment for your cancer. This study is investigating whether a new type of HER2-targeted drug is safe and effective. It will also determine the most effective dose of the drug that can be used safely. The drug being studied is called ZW25. This study is also open to patients with other types of HER2-positive cancers.


This is a Phase I trial

Durvalumab & Olaparib in Advanced Triple Negative Breast Cancer Treated with Chemotherapy

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (NCT03167619)

Summary

To take part in this study, you must have advanced (some stage III that is inoperable) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-), have already been treated with at least three cycles of a platinum-based chemotherapy and shown response, and have had no more than two prior chemotherapy regimens for metastatic breast cancer.

This study will compare the effects (good or bad) of using the targeted therapy olaparib (Lynparza®) alone or with an immunotherapy drug. Lynparza is approved to treat HER2-negative metastatic breast cancer in patients who test positive for an inherited BRCA mutation. It is a PARP inhibitor, a drug that blocks the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. Durvalumab (Imfinzi®) is a type of immunotherapy called a PD-L1 (programmed cell death ligand-1) inhibitor. It has been approved to treat certain other types of cancers, and its use in breast cancer is considered experimental.


This is a Phase II trial

BLZ945 Alone or With PDR001 For Metastatic Breast (and Other) Cancer

A Basket Study: A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors (NCT02829723)

Summary

This study has two parts. To enroll in the first part, you must have metastatic breast cancer. To enroll in the second part, you must have metastatic triple negative breast cancer. This study is investigating whether a new type of targeted cancer drug is safe and effective when it is given alone or with an immunotherapy drug. This is the first study to test this new targeted drug in cancer patients. The targeted drug being used in this study is called BLZ945. It targets a receptor called CSF1R that plays a role in tumor growth. Some patients who enroll in this study will also receive an immunotherapy drug called PDR001. This study is also enrolling patients with other types of metastatic cancers.


This is a Phase I-II trial

Pembrolizumab (Immunotherapy) And Radiosurgery (Radiation) to Treat Brain Metastases

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients (NCT03449238)

Summary

To take part in this study, you must have metastatic (stage IV) breast cancer and at least two brain metastases.

This study is investigating the safety and effects (good or bad) of using pembrolizumab (Keytruda®) along with stereotactic radiosurgery (SRS) to treat breast cancer that has spread to the brain. Keytruda is a type of immunotherapy called a PD-1 inhibitor. It stimulates the body's immune system to go after cancer cells. It has been approved to treat certain types of cancer, but its use in breast cancer is considered experimental. Stereotactic radiosurgery is not surgery. It is a type of radiation therapy that precisely targets metastases in the brain.


This is a Phase I-II trial

DS-8201a Versus T-DM1 for HER2-Positive Advanced Breast Cancer

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] (NCT03529110)

Summary

To take part in this study, you must have HER2 positive, advanced (some stage III) or metastatic (stage IV) breast cancer and have already been treated with T-DM1 (Kadcyla®).

This study is comparing the effects (good or bad) of an experimental HER2 targeted therapy called DS-8201 to the standard of care in patients with advanced breast cancer who have already been treated with the HER2 targeted therapy Kadcyla. DS-8201 is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells. The two standard of care options used in this study are the HER2 targeted therapy trastuzumab (Herceptin®) given with the chemotherapy drug capecitabine (Xeloda®) and the HER2-targeted therapy lapatinib (Tykerb®) given with Xeloda.


This is a Phase III trial

ONC201 for Estrogen Receptor Positive or Triple Negative Metastatic Breast Cancer

A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma (NCT03394027)

Summary

To take part in this study, you must have estrogen receptor positive or triple negative (ER-, PR- and HER2-) metastatic breast cancer.

This study will examine the safety and effectiveness of using an experimental drug called ONC201 to slow cancer growth. ONC201 is a new type of cancer drug called an impridone. This study is also enrolling women with advanced endometrial cancer.


This is a Phase II trial

Ibrance plus Femara or Faslodex for HR+, HER2- Metastatic Breast Cancer

A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (NCT03007979)

Summary

To take part in this study, you must have HR-positive (ER+/PR+), HER2-negative metastatic (stage IV) breast cancer. This study is evaluating a new dosing schedule for the targeted drug palbociclib (Ibrance®). If you are in this study you will receive Ibrance® for 5 days on with 2 days off, instead of the current standard schedule of 3 weeks on and 1 week off. You will also receive the anti-estrogen drugs letrozole (Femara®) and fulvestrant (Faslodex®). If you are premenopausal, you will receive a drug to shut down your ovaries.
This is a Phase II trial

A New Three-Drug Combination for HR+, HER2- Metastatic Breast Cancer

A Phase 1b/2a Study Of Palbociclib In Combination With Everolimus And Exemestane In Postmenopausal Women With Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer (NCT02871791)

Summary

To take part in this study, you must have hormone sensitive (ER+ and/or PR+), HER2-negative metastatic breast cancer. Researchers think using three drugs that work in different ways will be an effective breast cancer treatment. The three drugs patients who enroll in this study will receive are palbociclib (Ibrance®), everolimus (Afinitor®) and exemestane (Aromasin®). The researchers will determine the best dose of each drug to use when the three drugs are given together. All three drugs are used to treat metastatic breast cancer. It is not known how well they work when given together. Ibrance is a targeted drug that blocks two proteins, CDK 4 and CDK 6. Afinitor is a targeted drug that blocks mTOR. Aromasin is an anti-estrogen drug.
This is a Phase I-II trial

Ribociclib and Immunotherapy to Treat Metastatic Breast Cancer

A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer (NCT03294694)

Summary

To take part in this study you must have metastatic (stage IV) breast cancer that is hormone receptor positive and HER2-negative.

This study is evaluating the safety and effects (good or bad) of using ribociclib (Kisqali®) along with an immunotherapy or an immunotherapy and a hormone therapy. Kisqali is a type of targeted therapy called a CDK 4/6 inhibitor. It is approved for use along with an anti-estrogen therapy to treat HR-positive HER2-negative metastatic breast cancer. The aromatase inhibitor being used in this study is fulvestrant (Faslodex®). The immunotherapy being used in this study is spartalizumab (PDR001). It is a type of immunotherapy that targets PD-1. This study also is enrolling patients with metastatic ovarian cancer.


This is a Phase I trial

Study of MGD009 in Metastatic Breast (and other) Tumors With B7-H3

Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms (NCT02628535)

Summary

Scientists have found that many cancer cells have high levels of a protein called B7-H3. Blocking this protein may be an effective way to treat cancer. MGD009 is a new drug that recognizes B7-H3 on cancer cells. It works by getting immune cells to go after B7-H3-expressing cancer cells. This study is evaluating the safety, tolerability, and best dose of MGD009 for treating metastatic breast (and other) cancers that test positive for B7-H3. Patients will have their tumor tested for the B7-H3 protein. Those whose tumors test positive will be eligible for the study.


This is a Phase I trial

PF-05082566 With Kadcyla® or Trastuzumab For Advanced HER2 Positive Breast Cancer

A Phase 1B Dose Escalation Trial of Human Anti-4-1BB Agonistic Antibody PF-05082566 in Combination With Adotrastuzumab-Emtansine or Trastuzumab in Patients With HER2-Positive Advanced Breast Cancer (NCT03364348)

Summary

To take part in this study you must have HER2 positive advanced (some stage III) or metastatic (stage IV) breast cancer.

This study is investigating the safety and effects (good or bad) of using utomilumab (PF-05082566) with trastuzumab emtansine (Kadcyla®) or trastuzumab (Herceptin®). Utomilumab is an investigational immunotherapy that targets 4-1BB (CD-137), a molecule that stimulates the immune system. Herceptin is a HER2-targeted therapy approved to treat HER2 positive breast cancer. Kadcyla is an antibody-drug conjugate (ADC). It uses Herceptin to deliver the chemotherapy drug DM1 directly to the cancer cells. It is approved to treat HER2 positive metastatic breast cancer.


This is a Phase I trial

Study of U3-1402 for HER2 Negative, HER3 Positive Advanced Breast Cancer

Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer (NCT02980341)

Summary

To take part in this study you must have advanced (stage III) or metastatic (stage IV) breast cancer that is HER2 negative and HER3 positive and have had 2-6 prior chemotherapy regimens, at least 2 of which were for advanced cancer, and at least 1 that included a taxane.

This study will evaluate the safety, effects (good or bad) and best dose of U3 1402. This drug is an investigational antibody-drug conjugate (ADC). It uses an antibody that targets HER3 on cancer cells to deliver a chemotherapy drug called MAAA-1181a directly to these cells.


This is a Phase I-II trial

Taselisib with HER2-Targeted Therapies for Advanced HER2+ Breast Cancer

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (NCT02390427)

Summary

Taselisib (GDC-0032) is a new type of drug called a PI3K inhibitor. It works by blocking the PI3K protein, which plays a role in cancer cell growth. Researchers think using Taselisib along with HER2-targeted therapies will be a more effective way to treat advanced HER2+ breast cancer. Pertuzumab (Perjeta®), trastuzumaub (Herceptin®), and T-DM1 (Kadcyla®) are three different HER2-targeted therapies. Paclitaxel (Taxol®) is a chemotherapy drug commonly used to treat breast cancer. This study is looking at the safety, effectiveness, and best dose of taselisib when it is given along with one or more HER2-targeted therapies to patients with locally recurrent or metastatic HER2+ breast cancer.
This is a Phase I trial

Prexasertib and Lynparza in Patients With Advanced Breast (and Other) Cancer

A Basket Study: Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors (NCT03057145)

Summary

To take part in this study, you must have advanced (stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good and bad) of using two types of targeted drugs to treat advanced breast cancer. The two drugs being used are Lynparza and prexasertib (LY2606368). Lynparza is approved by the FDA for the treatment of ovarian cancer. Laboratory studies suggest giving prexasertib with Lynparza will make Lynparza more effective. This study is also recruiting patients with other types of cancer.


This is a Phase I trial

Keytruda with INCB039110 or INBC050465 for Advanced Breast (and Other Solid) Tumors

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors (NCT02646748)

Summary

Pembrolizumab (Keytruda®) targets a protein called programmed cell death-1 (PD-1). Blocking this protein gets the immune system to kill cancer cells. NCB039110 and INCB050465 are two new experimental targeted therapies. INCB039110 works by inhibiting the JAK pathway. INCB050465 works by inhibiting the PI3K pathway. There are two parts to this study. In the first part, the researchers will determine the best dose of INCB039110 or INCB050465 to use with Keytruda. In the second part, the researchers will use the best dose of INCB039110 or INCB050465 along with Keytruda to test its safety and effectiveness in patients with advanced breast cancer. To be eligible for the second part of the study, patients must have progressed on or not previously been treated with a PD-1 pathway targeted therapy. This study also is enrolling patients with other types of solid tumors.


This is a Phase I trial

MEDI4736 with Lynparza or Cediranib for Advanced Breast (and Other Solid) Tumors

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancer (NCT02484404)

Summary

MEDI4736 (durvalumab) is an immunotherapy drug that works by blocking a protein called PD-L1 (programmed cell death ligand-1). Blocking this protein allows the body's immune system to go after cancer cells. Olaparib (Lynparza®) is a type of cancer drug called a PARP inhibitor. PARP inhibitors interfere with the cancer cells' DNA, making them more sensitive to chemotherapy. Lynparza is used to treat advanced ovarian cancer in women who have an inherited BRCA1/2 mutation. In phase 1 of this study, researchers studied the safety and effectiveness of using MEDI4736, Lynparza or cediranib to treat advanced breast (and other solid) tumors. Phase 1 is now completed. Phase 2 of this study is open to triple-negative breast cancer patients combining MEDI4736 and olaparib. To be eligible, patients must not have previously been treated with PARP inhibitors, PD-1 or PD-L1 inhibitor or an anti-CTLA4 therapy and not have had more than 3 lines of previous treatments for metastatic disease.


This is a Phase I-II trial

Tecentriq, Perjeta and Hercptin for HER2+ Breast Cancer That Has Spread to the Brain

A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer(NCT03417544)

Summary

To take part in this study, you must have HER2-positive, metastatic (stage IV) breast cancer that has spread to the brain. This study is evaluating the safety and effects (good or bad) of using an immunotherapy drug along with a HER2 targeted drug to treat HER2+ metastatic breast cancer. The immunotherapy drug is atezolizumab (Tecentriq®). It is approved to treat certain types of lung and bladder cancers. It gets the immune system to go after cancer cells by blocking a protein called PD-L1 (programmed cell death-ligand 1). The two HER2-targeted drugs used in this study are pertuzumab (Perjeta®) and trastuzumab (Herceptin®).
This is a Phase II trial

Evaluating a New Targeted Therapy for HER2-Positive Advanced Breast Cancer

A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer(NCT03262935)

Summary

To take part in this study, you must have HER2-positive advanced (some stage III) or metastatic (stage IV) breast cancer. This study is comparing the safety and effects (good or bad) of a new targeted drug to a physician's choice standard treatment for advanced HER2+ breast cancer. The new targeted therapy is called SYD985. It is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells. The physician's standard of care drug combination will include two of the following: lapatinib (Tykerb®), capecitabine (Xeloda®), trastuzumab (Herceptin®), vinorelbine (Navelbine®), or eribulin (Halaven®).
This is a Phase III trial

Molecular Profiling-Based Targeted Therapies for Metastatic Breast (and Other) Cancer

A Basket Study: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2) (NCT02152254)

Summary

Molecular profiling of a tumor may identify genetic mutations or biomarkers that suggest the tumor is likely to respond to a currently available targeted therapy. It is not known if choosing metastatic breast (or other types of) cancer based on the tumor's molecular profile is more effective than the current standard of care. All patients who enroll in this study will have molecular profiling performed on a biopsy of their tumor. If there is no mutation or biomarker found, the patient will receive the treatment their doctor determines is the best option. If a mutation or biomarker is found and there is an FDA-approved drug for the tumor type, patients will be offered that treatment. If there is a mutation or biomarker found but no FDA-approved drug that targets it, patients will be randomly assigned to either a targeted therapy or the standard of care.

First Study of AZD8186 in Patients

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC)... (NCT01884285)

Summary

AZD8186 is a new cancer therapy that works by inhibiting PI3K, a group of proteins that help cancer cells to grow. It is designed specifically for cancers that are characterized as being deficient in PTEN, a gene that regulates cell growth. The purpose of this study is to determine the safest, best dose of AZD8186 in PTEN-deficient cancers. This trial is enrolling individuals with triple negative breast cancer as well as other cancers.


This is a Phase I trial

Treating Advanced Cancer By Choosing Targeted Therapy Based on Tumor's Genetic Makeup

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study (NCT02693535)

Summary

This study is evaluating the safety and effectiveness of using the tumor's genetic alterations to select an FDA-approved targeted therapy for treatment. In this study, the targeted therapy each patient receives will be selected based on their tumor's specific genetic profile. To be eligible, individuals must have no available standard therapy options. This study is enrolling patients with advanced breast and other cancers.


This is a Phase II trial

Ribociclib and Faslodex for HR+, HER2- Advanced Breast Cancer

A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT02632045)

Summary

Ribociclib (LEE011) is a type of targeted therapy called a cyclin-dependent kinase (CDK) inhibitor. It works by inhibiting two enzymes, CDK4 and CDK6. Fulvestrant (Faslodex®) is an anti-estrogen therapy used to treat advanced breast cancer in postmenopausal women. This study is comparing the safety and effectiveness of Faslodex and ribocicilib to Faslodex and a placebo for treating HR+, HER2- advanced breast cancer. To be eligible, participants must have had their cancer progress after receiving an aromatase inhibitor (letrozole, exemestane, or anastrozole), and be in the process of switching their hormone therapy.
This is a Phase II trial

Xentuzumab & Abemaciclib & an Anti-Estrogen Drug for Advanced Breast Cancer

An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts (NCT03099174)

Summary

To take part in this study, you must have HR-positive (ER+/PR+), HER2-negative advanced (some stage III) or metastatic (stage IV) breast cancer. This study will identify the best dose, safety and effectiveness for two new targeted drugs. The drugs will be given along with an anti-estrogen drug. The two new targeted drugs are xentuzumab (BI 836845) and abemaciclib (LY2835219). The anti-estrogen drug you are given will be letrozole (Femara®), anastrozole (Arimidex®) or fulvestrant (Faslodex®).
This is a Phase I trial

CDK-Inhibitor for Previously Treated Metastatic Disease

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790)

Summary

A new target for treating metastatic breast cancer may be cyclin-dependent kinase (CDK), a family of enzymes involved in cell growth. As the name implies, CDK enzymes are only active in the presence of proteins referred to as cyclins. PD 0332991 (Palbociclib) is a new biological therapy that blocks two different cyclin-dependent kinase enzymes. This, in turn, may slow or stop a cancer's growth. The goal of this trial is to determine the side effects of Palbociclib and how well it works in treating patients with tumors that are no longer responding to standard treatment.


This is a Phase II trial

Neratinib plus a Targeted Therapy for Advanced Breast (and Other) Cancer

Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation (NCT03065387)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. This study is comparing the safety, best dose and effects (good or bad) of using a new type of targeted therapy in combination with Afinitor, Ibrance, or Mekinist to treat advanced cancers that are EGFR+, HER2+, HER3+ or HER4+. The new targeted therapy is neratinib (Nerlynx®). It is a kinase inhibitor that works by blocking several enzymes that promote cell growth. It is approved to treat early-stage HER2+ breast cancer. Everolimus (Afinitor®) is an mTOR inhibitor. It is a targeted therapy used to treat advanced hormone-sensitive breast cancer. Palbociclib (Ibrance®) is a CDK4/6 inhibitor. It is a targeted therapy used to treat ER+, HER2- breast cancer. Trametinib (Mekinist®) is an MEK inhibitor. It is a targeted therapy used to treat some types of melanoma and lung cancer. This study is enrolling patients with other types of advanced cancer.
This is a Phase I trial

Ribociclib with Herceptin or Kadcyla for Advanced HER2-Positive Breast Cancer

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer (NCT02657343)

Summary

Ribociclib (LEE011) is a new type of targeted therapy called a CDK 4/6 inhibitor. Trastuzumab (Herceptin®) and T-DM1 (Kadcyla®) are targeted therapies routinely used to treat HER2-positive breast cancer. This study is investigating the safety and best dose of ribociclib when given in combination with Herceptin or Kadcyla to treat individuals with advanced HER2-positive breast cancer that has not responded to standard treatment.


This is a Phase I-II trial

Keytruda, Femara & Ibrance for ER+ Metastatic Breast Cancer After Femara & Ibrance

Phase II Study of the Addition of MK-3475 (Pembrolizumab) to Letrozole and Palbociclib in Patients With Metastatic Estrogen Receptor Positive Breast Cancer Who Have Stable Disease But Are Not Responding to Letrozole and Palbociclib (NCT02778685)

Summary

To take part in this study, you must have estrogen receptor-positive (ER+), HER2-negative, metastatic breast cancer. You must have also already been treated with letrozole (Femara®) and palbociclib (Ibrance®). Femara and Ibrance are an approved breast cancer combination. Femara is an anti-estrogen drug. Ibrance is a targeted treatment. Researchers think adding an immunotherapy drug to this combination will make the combination work better in women who already tried it. The immunotherapy drug that will be used in this study is pembrolizumab (Keytruda®). Keytruda is used to treat certain types of melanoma, lung cancer and head and neck cancers. It is available as a breast cancer treatment only in clinical trials.
This is a Phase II trial

MEDI4736 & Lynparza in Metastatic HER2- Breast Cancer in Women with a BRCA Mutation

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors (NCT02734004)

Summary

Olaparib (Lynparza) is a new type of targeted therapy called a PARP inhibitor. It works by blocking the PARP protein from repairing damaged DNA in cancer cells. Lynparza is approved for treating advanced ovarian cancer in women with a BRCA mutation. MEDI4736 is an immunotherapy that blocks PD-L1 (programmed cell death-ligand 1) protein. Blocking this protein stimulates the immune system to go after cancer cells. This study is investigating the safety and effectiveness of using Lynparaza and MEDI4736 together to treat women with HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation.


This is a Phase I-II trial

DS-8201a for HER2-Low Advanced Breast Cancer

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects [DESTINY-Breast04] (NCT03734029)

Summary

To take part in this study you must have HER2-low advanced (some stage III) or metastatic (stage IV) breast cancer. This study is comparing the safety and effects (good or bad) of the new targeted therapy DS-8201a to the standard of care. HER2-low tumors are IHC/FISH 1+ or 2+. DS-8201a is an antibody-drug conjugate (ADC). It uses a HER2 antibody to deliver a topoisomerase I inhibitor directly to cancer cells.
This is a Phase III trial

Selumetinib and Lynparza for Advanced Breast (and Other) Cancer

Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance (NCT03162627)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating whether it is safe and effective to use the drug selumetinib along with olaparib (Lynparza®) to treat advanced breast cancer. Selumetinib (AZD6244) is an experimental targeted drug called an MEK inhibitor. Olaparib (Lynparza®) is a type of targeted drug called a PARP inhibitor. It is approved to treat certain types of ovarian cancer. This study is also recruiting individuals with other types of cancer.


This is a Phase I trial

INCB054828 for Advanced Breast (and Other) Cancers

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (NCT02393248)

Summary

INCB054828 is a new targeted therapy that is designed to block the FGF (fibroblast growth factor) or FGFR (fibroblast growth factor receptor) protein. Laboratory studies show that targeting the FGF or FGFR protein may be an effective way to slow or stop cancer cell growth. In this study, researchers will determine the maximum tolerated dose of INCB054828 alone and in combination with standard therapy for individuals with advanced breast (and other) solid tumors.


This is a Phase I-II trial

PRS-343 in HER2-Positive Advanced Breast Cancer

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors (NCT03330561)

Summary

To take part in this study you must have HER2-positive locally advanced (stage III) or metastatic (stage IV) breast cancer.

This study is testing the safety and effect (good or bad) of PRS-343, an experimental cancer drug. PRS-343 is a new type of cancer treatment. The drug is a HER2-targeted therapy that also stimulates the immune system. This study is also enrolling patients with other types of solid tumors.


This is a Phase I trial

MLN0128 and Alisertib for Metastatic Triple-Negative Breast (and Other Advanced) Cancers

A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC) (NCT02719691)

Summary

This study is investigating whether it is safe and effective to combine two new cancer drugs. Both drugs are targeted therapies. One drug is called MLN0128. The other is called Alisertib (MLN8237). To take part in this study, you must have metastatic triple negative breast cancer and you must have already been treated with chemotherapy.

MLN0128 is a new type of targeted therapy called an mTOR inhibitor. Alisertib (MLN8237) is a new targeted therapy that blocks an enzyme--Aurora A kinase--that helps cancer cells grow. This trial is also enrolling patients with other types of cancer.
This is a Phase I trial

Ibrance, Bavencio and Faslodex for Previously Treated ER+, HER2- Advanced Breast Cancer

Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (NCT03147287)

Summary

To take part in this study, you must have HR+, HER2-negative locally recurrent (some stage III) or metastatic (stage IV) breast cancer. You must have already been treated with a CDK4/6 inhibitor in combination with an anti-estrogen therapy. This study is investigating the safety and effects (good and bad) of using fulvestrant (Faslodex®) alone, in combination with Ibrance®, and in combination with Ibrance and Bavencio®. Faslodex is the anti-estrogen drug used in this study. Palbociclib (Ibrance®) is approved to treat HR+, HER2-negative breast cancer in combination with an anti-estrogen therapy. Avelumab (Bavencio®) is a type of immunotherapy called a PD-L1 inhibitor. It is approved to treat a type of blood cancer.
This is a Phase II trial

Cediranib + Lynparza for Metastatic Triple Negative Breast Cancer (and Other Solid Tumors)

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613)

Summary

This trial is studying the safety and effectiveness of treating metastatic breast cancer (and other solid tumors) with two drugs: Olaparib (Lynparza®) and Cediranib. To take part, you must have metastatic triple negative breast cancer and not have an inherited BRCA 1/2 mutation. Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. Cediranib is a type of drug called an angiogenesis inhibitor. Giving cediranib with Lynparza may make the Lynparza more effective.


This is a Phase II trial

177Lu-J591 to Treat Metastatic Breast (and Other Solid) Tumors

177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study (NCT00967577)

Summary

Scientists are trying to find new ways to kill cancer cells that have spread throughout the body. 177Lu-J591 is a new drug that uses radiation to kill cancer cells. To take part, you must have metastatic breast cancer, and have no other treatment options available.

177Lu-J591 combines two chemicals J591 and 177Lutetium (177Lu). J591 is a protein that attaches to a molecule found on the blood vessels of cancer cells. 177Lu is a radioactive molecule. Scientists think that it can find and kill the blood vessels that help cancer cells grow.

Abemaciclib and Keytruda for HR+, HER2- Metastatic Breast (and Non-Small Cell Lung) Cancer

A Phase 2 Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT02779751)

Summary

To take part in this study, you must have hormone sensitive (ER+/PR+), HER2-negative metastatic (stage IV) breast cancer. This study is investigating whether it is safe and effective to give a new type of targeted treatment along with an immunotherapy drug. The new targeted treatment is called abemaciclib (LY2835219). It is a type of targeted drug called a CDK 4/6 inhibitor. It only is available in clinical trials. Pembrolizumab (Keytruda®) is the immunotherapy drug being used in this study. Keytruda is approved to treat melanoma and non-small cell lung cancer. Its use in breast cancer is considered experimental. This study is also recruiting individuals with metastatic non-small cell lung cancer.
This is a Phase I trial

Targeted and Hormone Therapies plus Ibrance for HER2+, HR+ Metastatic Breast Cancer

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (PATINA) (NCT02947685)

Summary

To take part in this study, you must have HER2-positive, HR-positive (ER+/PR+) advanced (some stage III) or metastatic (stage IV) breast cancer. You must have already had at least 4 and at most 8 cycles of a HER2-targeted drug. This study is comparing the safety and effects (good and bad) of using a targeted drug along with the standard of care for treating HER2+, HR+ advanced breast cancer to the standard of care alone. The standard of care is a HER2-targeted drug and an anti-estrogen drug. The targeted drug being used in this study is palbociclib (Ibrance®). It is approved for treating metastatic breast cancer.
This is a Phase III trial

Keytruda® and Binimetinib for Advanced Triple Negative Breast Cancer

Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer(NCT03106415)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effectiveness of using an immunotherapy along with a targeted therapy to treat triple negative breast cancer. Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It is currently approved to treat certain types of melanoma, head and neck cancer, lung cancer and Hodgkin lymphoma. Binimetinib (MEK162) is a type of targeted therapy called an MEK inhibitor.


This is a Phase I-II trial

ONC201 and Methionine-Restricted Diet in Patients With Advanced Triple Negative Breast Cancer

ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer (NCT03733119)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer and currently do not follow a vegan or vegetarian diet.

This study will compare the safety and effects (good or bad) of a targeted therapy called ONC201 in patients who are or are not on a methionine-restricted (low-protein) diet. ONC201 is an experimental targeted therapy that targets Akt/ERK and can lead to the death of a tumor cell. Methionine is an essential amino acid that is found in foods that contain protein. The researchers want to see if restricting the amount of methionine in a patient's diet affects how the cancer responds to the drug ONC201.


This is a Phase II trial

LSZ102 Alone or With Ribociclib or Alpelisib in ER+ Advanced Breast Cancer

A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy (NCT02734615)

Summary

Researchers are developing new drugs to treat hormone-sensitive metastatic breast cancer. LSZ102 is a new drug that works by destroying the estrogen receptor. In this study, researchers will determine the best dose of LSZ102 to give alone or in combination with a targeted drug. The two targeted drugs are called ribociclib and alpelisib. To take part in this study, you must have ER+ advanced or metastatic breast cancer and already have been treated with hormone therapy.
This is a Phase I trial

Anetumab Ravtansine in Advanced Triple Negative Tumors That Are Mesothelin-Positive

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies (ARCS-Multi) (NCT03102320)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR-, HER-) that tests positive for mesothelin, a protein that some tumors overproduce.

The purpose of this study is to test the safety and effects (good or bad) of anetumab ravtansine, a targeted therapy that blocks mesothelin, a protein that helps cells stick together.


This is a Phase I trial

A New PARP Inhibitor For BRCA-Positive Advanced Breast Cancer

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations (NCT01989546)

Summary

BMN 673 is a new type of cancer drug called a PARP inhibitor. It works by blocking the PARP--poly (ADP-ribose) polymerase--protein that helps cells repair DNA damage. Early studies suggest BMN 673 may be effective in patients with advanced breast cancer who have a BRCA mutation. This study is evaluating the effect that BMN673 has on cancer cells (through tumor biopsies) of patients with advanced breast cancer who have a known BRCA inherited mutation.


This is a Phase I-II trial

Orteronel For Androgen Receptor-Positive Metastatic Breast Cancer

A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) (NCT01990209)

Summary

Orteronel (TAK-700) is a new type of cancer drug that works by blocking the androgen receptor (AR). It is currently in phase III trials for prostate cancer. Studies have found that about 70-90 percent of primary breast tumors and 75 percent of breast metastases are AR+. Researchers believe orteronel may be an effective treatment for individuals with metastatic breast cancer whose tumors are AR+. This study is investigating the effectiveness of orteronel in individuals with triple negative or ER+ and/or PR+ metastatic breast cancer that is AR+. The researchers will test tumor tissue from a previous biopsy to determine if a tumor is AR+.
This is a Phase II trial

Gedatolisib with Ibrance and Femara or Faslodex in ER+ HER2- Metastatic Breast Cancer

Phase 1b Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer (MBC) (NCT02684032)

Summary

Researchers are studying new treatment combinations for metastatic breast cancer. Palbociclib (Ibrance®) is a targeted drug that is used to treat metastatic breast cancer. It is given along with hormone therapy--either letrozole (Femara®) or fulvestrant (Faslodex®). This study is looking at the best dose of gedatolisib to add to the combination. To take part in this study, you must have ER-positive and HER2-negative metastatic breast cancer.


This is a Phase I trial

Olaparib for Metastatic Breast Cancer with an Inherited Genetic Mutation

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded) (NCT03344965)

Summary

To take part in this study, you must have metastatic (stage IV) breast cancer and have an inherited DNA repair gene mutation that was identified through genetic testing of the tumor or through a blood test. This study is investigating whether olaparib (Lynparza®) is effective for treating metastatic breast cancer in women and men with a tumor that has a DNA repair gene mutation, such as BRCA1 or BRCA2. Olaparib (Lynparza®) is a type of targeted therapy known as a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. Lynparza is currently approved to treat recurrent ovarian cancer and HER2-negative metastatic breast cancer.


This is a Phase II trial

AZD6738 with Chemotherapy and/or Olaparib in Advanced Breast Cancer

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.(NCT02264678)

Summary

To take part in this study you must have advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety, effects, and best dose of AZD6738 when it is used alone or with the chemotherapy drug carboplatin or the PARP inhibitor olaparib (Lynparza®). AZD6738 is a new type of targeted therapy called an ATR inhibitor. It disrupts a cancer cell's ability to repair its own DNA, which can cause the cancer cells to die. Carboplatin is a chemotherapy drug used to treat breast cancer. Lynparza is a PARP inhibitor approved to treat BRCA+ metastatic breast cancer.
This is a Phase I-II trial

ZW49 in Patients With Advanced HER2-Positive Breast Cancer

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers (NCT03821233)

Summary

To take part in this study you must have HER2 positive advanced (some stage III) or metastatic (stage IV) breast cancer.

This study is evaluating the safety, side effects and best dose of a new targeted therapy called ZW49. ZW49 uses an antibody that can attach to HER2 proteins to deliver chemotherapy directly to the cancer cells. This is the first study to evaluate this drug in humans. It is also enrolling patients with other types of HER positive tumors.


This is a Phase I trial

FATE-NK100 with Herceptin for HER2+ Advanced Breast Cancer

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (DIMENSION) (NCT03319459)

Summary

To take part in this study, you must have HER2-positive, advanced (some stage III) or metastatic (stage IV) breast cancer. This study is looking at the safety and effects (good or bad) of using an immunotherapy drug along with Herceptin to treat HER2-positive advanced breast cancer. The immunotherapy drug is called FATE-NK100. It is only available in clinical trials. Herceptin is a targeted therapy approved to treat HER2-positive breast cancer.


This is a Phase I trial

9-ING-41 Targeted Therapy With or Without Chemotherapy for Patients With Advanced Breast Cancer

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors (NCT03678883)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and have no other standard treatment options available.

This study is determining the safety and the effects (good or bad) of the investigational targeted therapy 9-ING-41 when it is used with or without chemotherapy. The drug 9-ING-41 is a type of targeted therapy called a GSK-3β inhibitor. This study is also enrolling patients with other types of cancer.


This is a Phase I-II trial

GDC-9545 plus Ibrance for Locally Advanced or Metastatic ER+ Breast Cancer

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (NCT03332797)

Summary

To take part in this study, you must have ER-positive, HER2-negative locally advanced (some stage III) or metastatic (stage IV) breast cancer. This study is evaluating the safety and effects (good or bad) of giving GDC-9545 alone or with Ibrance to treat advanced breast cancer. GDC-9545 is the experimental drug being used in this study. Palbociclib (Ibrance®) is a type of targeted therapy that keeps cancer cells from growing by blocking two proteins, CDK 4 and CDK 6. It is approved by the FDA to treat postmenopausal women with ER+, HER2- metastatic breast cancer. Luteinizing hormone-releasing hormone (LHRH) agonist keeps the ovaries from making estrogen and progesterone.
This is a Phase I trial

Immunotherapy (PDR001) With a Targeted Therapy for Advanced Triple Negative Breast Cancer

Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)(NCT02900664)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer and have already had at least one prior treatment that your cancer progressed on or did not respond to. Researchers are studying the safety and effects (good or bad) of a new immunotherapy drug when it is given along with a targeted drug for treating advanced or metastatic triple negative breast cancer. If you enroll in this study will receive the immunotherapy drug PDR001. You will also receive one of four targeted drugs: Canakinumab (Ilaris®), CJM112, trametinib, or EGF816. This study is also enrolling patients with other types of cancer.


This is a Phase I trial

Faslodex and Xtandi for ER+, HER2- Metastatic Breast Cancer

Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer (NCT02953860)

Summary

To take part in this study, you must have ER-positive, HER2-negative metastatic (stage IV) breast cancer. Your tumor must also be androgen receptor positive (AR+). This tumor test will be done by the researchers. This study is investigating the the safety and effects (good and bad) of using an anti-estrogen drug and an anti-androgen drug to treat ER+, HER2- metastatic breast cancer. The anti-estrogen drug used in this study is fulvestrant (Faslodex®). It is approved to treat postmenopausal women with metastatic breast cancer. The anti-androgen drug is enzalutamide (Xtandi®). It is approved to treat prostate cancer. If you are premenopausal, you will also receive a drug to shut down your ovaries.
This is a Phase II trial

Palbociclib With Fulvestrant for ER+, HER2- Advanced Breast Cancer

Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor (NCT02738866)

Summary

To take part in this study you must have ER positive, HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer and have already been treated with palbociclib (Ibrance®) and an aromatase inhibitor.

This trial is investigating the safety and effects (good and bad) of using Ibrance and Faslodex to treat women and men with advanced breast cancer who have previously been treated with Ibrance and an aromatase inhibitor. Ibrance is a CDK4/6 inhibitor approved to treat HR positive, HER2 negative breast cancer in combination with an anti-estrogen therapy. Faslodex is an anti-estrogen therapy approved to treat postmenopausal women with metastatic breast cancer.


This is a Phase II trial

A166 for HER2 Positive and HER2 Low Expression Advanced Breast Cancer

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies (NCT03602079)

Summary

To take part in this study, you must have HER2 positive or low HER2 expression advanced (some stage III) or metastatic (stage IV) breast cancer that has not responded to standard therapies.

This study is evaluating the safety and effects (good and bad) of the experimental therapy A166 in women and men with advanced breast cancer. A166 is an antibody-drug conjugate (ADC). It combines chemotherapy with a HER2 targeted therapy, allowing it to deliver the chemotherapy directly to the cancer cells. This study is also enrolling patients with other types of advanced cancer.


This is a Phase I-II trial

Arimidex, Ibrance, Herceptin and Perjeta for HR+, HER2+ Metastatic Breast Cancer

A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer (NCT03304080)

Summary

To take part in this study, you must have HR+ (ER+/PR+), HER2+ metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of using two anti-estrogen targeted therapies and two HER2-targeted therapies to treat HR+, HER2+ metastatic breast cancer. The anti-estrogen therapies being used in this study are palbociclib (Ibrance®) and anastrozole (Arimidex®). The HER2-targeted therapies are trastuzumab (Herceptin®) and pertuzumab (Perjeta®). All four therapies are approved to treat metastatic breast cancer.
This is a Phase I-II trial

AVID100 in Advanced Epithelial Carcinomas

Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin (NCT03094169)

Summary

To take part in this study you must have advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has not responded to other treatment options and tests positive for EGFR over-expression.

This study is to determine the safety and effects (good or bad) of using an experimental targeted therapy called AVID100. AVID100 is a targeted antibody-drug conjugate (ADC). It targets EGFR proteins to deliver a chemotherapy drug called maytansinoid mertansine (DM1). This study is also enrolling patients with other types of tumors that test EGFR positive.


This is a Phase I-II trial

BMS-986158 for Advanced Triple Negative Breast (and Other) Cancer

A Basket Study: A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors (NCT02419417)

Summary

To take part in this study, you must have advanced (some stage III) and stage IV triple negative (ER-/PR-/HER2-) breast cancer. This study is investigating whether a new targeted drug for triple negative breast cancer is safe and effective. The new drug being studied is called BMS-986158. It is currently only available in clinical trials. This study also is enrolling patients with other types of advanced cancers.


This is a Phase I-II trial

CX-2009 for Advanced Breast (and Other) Cancer

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009) (NCT03149549)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer.

This study in investigating the safety and effects (good and bad) of a new immunotherapy for treating advanced breast cancer. CX-2009 A166 is an antibody-drug conjugate (ADC). It combines chemotherapy with targeted therapy, allowing it to deliver the chemotherapy directly to the cancer cells. This trial is also enrolling patients with other types of solid tumors.


This is a Phase I-II trial

PF-06804103 in HER2+ Advanced Breast Cancer

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS (NCT03284723)

Summary

To take part in this study you must have locally advanced (stage III) or metastatic (stage IV) HER2+ breast cancer and have no standard treatment options available. This study is investigating the safety and effect (good or bad) of PF-06804103. This investigational therapy is an antibody drug conjugate (ADC). It uses a HER2-targeted agent to deliver the chemotherapy drug Auristatin-0101 directly to HER2+ cancer cells. This study is also enrolling patients with other types of HER2+ solid tumors.
This is a Phase I trial

Neratinib for HER2-Positive Brain Metastases

A Phase II Trial of HKI-272 (Neratinib) for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases (NCT01494662)

Summary

Brain metastases are difficult to treat because many drugs are unable to cross the blood-brain barrier, which means they cannot enter the brain from the bloodstream. The experimental drug Neratinib (HKI-272) is a tyrosine kinase inhibitor. It works by blocking the HER2 and EGFR receptors, both of which are involved in cancer cell growth. Neratinib is a much smaller molecule than Herceptin® (the drug widely used to treat HER2+ tumors), and it is able to cross the blood-brain barrier. The goal of this trial is to determine how well neratinib works in treating breast cancer that has spread to the brain, as well as the effect that it has on cognitive functioning.
This is a Phase II trial

SGN-LIV1A in HER2-Negative Metastatic Breast Cancer

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer (NCT01969643)

Summary

Antibody-drug conjugate (ADC) is a cancer therapy that combines an antibody that targets cancer cells with a drug that can kill cancer cells. Because the antibody only targets cancer cells, the drug does not kill normal cells, making it less likely to cause side effects. SGN-LIV1A is an ADC that targets LIV-1 (SLC39A6), a protein that is expressed by most breast cancer cells, and delivers a cancer drug called monomethyl auristatin E. This study will assess the safety, highest tolerable dose and anti-tumor activity of SGN-LIV1A in women with HER2-negative metastatic breast cancer. To be eligible, participants must have triple negative metastatic breast cancer or HER2-negative, hormone sensitive metastatic breast cancer that can no longer be treated with a hormone therapy.


This is a Phase I trial

PF-06873600 for Metastatic HER2-Negative Breast Cancer

Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy (NCT03519178)

Summary

To take part in this study you must have metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor positive, HER2 negative breast cancer and have already been treated with a CDK 4/6 inhibitor.

This study is evaluating the safety and effects (good or bad) of PF-06873600, a new targeted therapy. PF-06873600 is a cyclin-dependent kinase (CDK) inhibitor. It works by inhibiting the CDK enzymes that help cancer cells grow. Patients in the study with hormone-receptor positive breast cancer will also be treated with an anti-estrogen therapy.


This is a Phase II trial

Two Targeted Therapies with Tocilizumab for HER2+ Metastatic Breast Cancer Resistant to Herceptin

A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab (NCT03135171)

Summary

To take part in this study, you must have HER2-positive metastatic (stage IV) breast cancer and you must have already been treated with Herceptin. This study is investigating the safety and effects (good and bad) of using three targeted drugs to treat HER2-positive metastatic breast cancer that has stopped responding to Herceptin. The three drug combination will use two HER2-targeted drugs—Herceptin and pertuzumab (Perjeta®)— along with tocilizumab (Actemra®). Laboratory studies suggest Actemra, a targeted drug approved to treat rheumatoid arthritis, may get HER2+ tumors to start responding again to Herceptin.
This is a Phase I trial

Neratinib for Advanced HER2-Positive Breast Cancer in Women and Men Age 60 and Older

Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer (NCT02673398)

Summary

To take part in this study, you must be age 60 or older and have locally advanced (stage III) or metastatic (stage IV) HER2-positive breast cancer. You must also not have previously been treated with neratinib (Nerlynx®). This study is looking at how well neratinib works in patients age 60 and older with HER2-positive advanced or metastatic breast cancer. Neratinib is a type of anti-cancer drug called a tyrosine kinase inhibitor. It is only available in clinical trials.


This is a Phase II trial

Veliparib and/or Tecentriq for BRCA+, Stage III-IV Triple Negative Breast Cancer

A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) (NCT02849496)

Summary

To take part in this study, you must have stage III or IV triple negative (ER-/PR-/HER2-) breast cancer. You must also test positive for the inherited BRCA1/2 mutation. This study is investigating how well two different types of cancer drugs work when they are used alone or together to treat stage III or IV triple negative breast cancer. The two drugs being used in this study are Veliparib (ABT-888) and atezolizumab (Tecentriq). Veliparib (ABT-888) is a new type of targeted drug called a PARP inhibitor. It is available only in clinical trials. Tecentriq is a new immunotherapy drug. It is approved to treat bladder cancer and a type of lung cancer.


This is a Phase II trial

GDC-0077 & Hormone Therapy with or without Ibrance for Advanced Breast Cancer

A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant... (NCT03006172)

Summary

To take part in this study, you must have advanced breast cancer (metastatic/stage IV and some stage III) that has a PIK3CA mutation. (Your tumor will be tested for a PIK3CA mutation to see if you are eligible.) This study is investigating the safety and effect of a new drug called GDC-0077 when it is used to treat advanced breast cancer that has a PIK3CA mutation. If your tumor is hormone-sensitive (ER+ and/or PR+) and HER2-negative you will receive GDC-0077 with a targeted drug and/or an anti-estrogen drug. Palbociclib (Ibrance®) is the targeted drug being used in this study. Letrozole (Femara®) and fulvestrant (Faslodex®) are the anti-estrogen drugs. All are approved breast cancer treatments.
This is a Phase I trial

Oral TTI-101 in Patients with Advanced Breast Cancer

Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers (NCT03195699)

Summary

To take part in this study you must have locally advanced (stage III) or metastatic (stage IV) breast cancer and no standard treatment options available.

This study is evaluating the safety, effects (good or bad), and best dose of TT1-101, a new oral cancer drug. TTI-101 is a tyrosine-kinase inhibitor that blocks STAT3, a protein that helps cancer cells grow. This study is also enrolling patients with other types of advanced cancer.


This is a Phase I trial

Lynparza Alone or With a New Drug That Targets DNA Repair in Metastatic TNBC

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant... (VIOLETTE) (NCT03330847)

Summary

To take part in this study you must have metastatic triple negative breast cancer that has been treated with up to two other drug therapies. Also, your tumor must have a mutation in genes that are part of the homologous recombination repair (HRR) pathway, which includes BRCA 1/2. Your tumor will be tested for mutations in these genes as part of the screening process. This study will compare the safety and effects (good and bad) of using olaparib (Lynparza®) alone to using Lynparza along with a new drug that targets DNA repair. Lynparza is a type of drug called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. The experimental drugs used in this study, AZD6738 and AZD1775, also target DNA damage repair.


This is a Phase II trial

  • Participation Time5 initial visits, then 1 visit every 2 months for 18 months, then 1 visit every 3 months
  • Participating research sites
    Research sites: 20 sites total

ARX788 for HER2 Positive Advanced Breast Cancer

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression (NCT03255070)

Summary

To take part in this study you must have HER2 positive advanced (some stage III) or metastatic (stage IV) breast cancer that has not responded to standard therapies and has already been treated with trastuzumab (Herceptin®).

This study is evaluating the safety, effects (good or bad) and best dose of ARX788. ARX788 is an antibody-drug conjugate (ADC). It uses an antibody that targets HER2 positive cancer cells to deliver a chemotherapy drug called amberstatin269 directly to these cells. This study is also enrolling patients with other types of advanced cancer.


This is a Phase I trial

Opdivo plus Cometriq for Metastatic Triple Negative Breast Cancer

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer(NCT03316586)

Summary

To take part in this study, you must be a woman with triple negative (ER-/PR-/HER2-) metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of using an immunotherapy and a targeted therapy to treat triple negative metastatic breast cancer. Nivolumab (Opdivo®) is the immunotherapy used in this study. It is a type of immunotherapy called a PD-1 (programmed cell death-1) inhibitor. It is approved to treat certain types of metastatic melanoma and non-small cell lung cancer. Cabozantinib (Cometriq®) is the targeted therapy that helps block the growth of the blood vessels tumors need to thrive. It is used to treat certain types of metastatic thyroid cancer.


This is a Phase II trial

AZD9833 With or Without Palbociclib in ER Positive and HER2 Negative Advanced Breast Cancer

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination With Palbociclib in Women With ER Positive, HER2 Negative Advanced Breast Cancer(NCT03616587)

Summary

To take part in this study, you must have ER positive and HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer that did not respond to standard therapies and, if metastatic, has not been treated with more than two different chemotherapy regimens.

This study will evaluate the safety and effect (good or bad) of AZD9833 alone or in combination with palbociclib (Ibrance®). AZD9833 is an experimental drug that targets the estrogen receptor and is being developed to treat ER positive, HER2 negative breast cancer. Ibrance is a targeted drug used to treat metastatic breast cancer. If you are premenopausal, you will also receive a drug that will put you in temporary menopause.


This is a Phase I trial

Targeted Therapy Recommendation Based on Genomic Profiling

A Basket Study: Registry Study for Personalized Cancer Therapy (NCT02508662)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and have already received a treatment that your cancer progressed on or did not respond to. If you take part in this study, researchers will review your medical records to learn about your tumor's genomic profile. This information will be used to recommend a targeted drug that is FDA-approved for patients who don't have breast cancer but do have tumors with the same genomic profile. This study is also recruiting patients with other types of advanced cancer.

Seribantumab Plus Faslodex for Postmenopausal Women With HR+ Advanced Breast Cancer

SHERBOC: A Double-blind, Placebo-controlled, Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (NCT03241810)

Summary

To take part in this study, you must be postmenopausal and have advanced (stage III) or metastatic (stage IV) breast cancer. You must have had no more than two prior therapies, one of which was a CDK inhibitor. This study is comparing the safety and effects (good and bad) of giving an anti-estrogen drug along with a new targeted therapy to giving an anti-estrogen drug along with a placebo in postmenopausal women with advanced breast cancer. The anti-estrogen drug being used in this study is fulvestrant (Faslodex®). It is commonly used to treat advanced breast cancer. The targeted therapy being used in this study is called seribantumab (MM-121).


This is a Phase II trial

LY2606368 For Metastatic Triple Negative or BRCA1/2-Associated Breast Cancer

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer at Low Genetic Risk. (NCT02203513)

Summary

LY2606368 is a new type of cancer drug called a Chk1/2 (checkpoint kinases 1/2) inhibitor. By blocking the activity of Chk1/2, LY2606368 may slow or stop cancer cell growth. Early studies suggest LY2606368 may be an effective treatment for certain types of breast tumors. This study is looking at whether LY2606368 can shrink tumors in patients with metastatic breast cancer who carry a BRCA1/2 mutation or who have a triple-negative (ER-, PR-, HER2-) tumor. To be eligible for this study, patients must have already tried standard treatments.


This is a Phase II trial

Immunotherapy LY3300054 Alone and in Combination in Advanced Breast Cancer

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) (NCT02791334)

Summary

To take part in this study you must have locally advanced (stage III) or metastatic (stage IV) breast cancer that is hormone receptor positive and HER2-negative or tests positive for high microsatellite instability (MSI-H). You must also have had at least 1 but no more than 3 chemotherapy regimens in the metastatic setting.

This study is testing the safety and effects (good or bad) of LY3300054 when it is used alone or in combination with a targeted therapy or an immunotherapy. LY3300054 is a type of immunotherapy called a checkpoint inhibitor. There are three other drugs being used in this study. LY3321367 is also an investigational checkpoint inhibitor. Ramucirumab (Cyramza) is a targeted therapy that blocks VEGFR-2, which keeps tumors from forming new blood vessels. It is approved to treat certain types of solid tumors, but not breast cancer. Abemaciclib (Verzenio) is a CDK 4/6 inhibitor approved to treat HR positive and HER2-negative metastatic breast cancer.


This is a Phase I trial

A Study of CDX-1140 as Monotherapy or in Combination in Pati...

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950)

Summary

To take part in this study you must have locally advanced (stage III) or metastatic (stage IV) breast cancer and have no other standard treatment options available.

This study is testing the safety, effects (good or bad) and best dose of the experimental cancer drug CDX-1140 when it is used alone or in combination with CDX-301, which is also an experimental cancer drug. CDX-1140 targets a protein called CD40, which is found on cancer cells. CDX-301 is a new type of tyrosine-kinase inhibitor. It is also a targeted therapy. This study is enrolling patients with other types of solid tumors.


This is a Phase I trial

Tecentriq & Cotellic or Idasanutlin for ER+, HER2- Advanced Breast Cancer

BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer (NCT03566485)

Summary

To take part in this study, you must have ER positive advanced (some stage III) or metastatic (stage IV) breast cancer.

This study is investigating the safety and effects (good or bad) of giving an immunotherapy along with a targeted therapy. The immunotherapy used in this study is the PD-L1 inhibitor atezolizumab (Tecentriq®). It works by stimulating the body's immune system to go after cancer cells. It is approved to treat certain types of cancers but its use in breast cancer is considered experimental. The two targeted therapies being used in this study are cobimetinib (Cotellic®), an MEK-targeted therapy approved to treat melanoma, and idasanutlin, a targeted therapy being studied in clinical trials.


This is a Phase I-II trial

PD-0332991 & T-DM1 in Advanced HER2+ Tumors with the Rb Protein

Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer (NCT01976169)

Summary

Researchers are looking for new ways to treat HER2+ breast cancer that has stopped responding to trastuzumab (Herceptin®) or other HER2-targeted therapies. PD-0332991 (Palbociclib) is a new targeted therapy that works by blocking two enzymes, CDK4 and CDK6, that play a role in cell growth. Studies suggest that palbociclib may be effective in tumors that test positive for a tumor suppressor protein called retinoblastoma (Rb). Scientists estimate that between 20% and 35% of breast cancers test positive for the Rb protein. T-DM1 (Kadcyla®) is a HER2-targeted therapy that combines the chemotherapy drug DM1 with trastuzumab. This study will identify the best dose of palbociclib to use along with T-DM1 to treat HER2-positive recurrent or metastatic breast cancer. To be eligible, participants must have a tumor that tests positive for the Rb protein.
This is a Phase I trial

PEN-866 for Triple Negative Advanced Breast (and Other) Cancer

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400)

Summary

To take part in this study, you must have triple negative (ER-/PR-HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer. This trial is investigating the safety and effects (good or bad) of a new type of targeted therapy called PEN-866. This study is also enrolling patients with other types of advanced cancer. This trial is the first study to test this drug in cancer patients.


This is a Phase I-II trial

Alisertib plus Fulvestrant for Advanced ER+, HER2- Breast Cancer

Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer (NCT02860000)

Summary

To take part in this study, you must be postmenopausal and have ER-positive, HER2-negative locally advanced (some stage III) or metastatic (stage IV) breast cancer. You must not have been treated with an aurora kinase inhibitor. This study is comparing the safety and effect of the targeted drug alisertib alone to the combination of alisertib and fulvestrant (Faslodex®) in postmenopausal women with locally advanced or metastatic breast cancer. Alisertib is an experimental targeted drug that blocks aurora A kinase. Faslodex is an anti-estrogen drug used to treat hormone-sensitive metastatic breast cancer in postmenopausal women.


This is a Phase II trial

Radiation Therapy, Palbociclib & Hormone Therapy for Breast Cancer Related Bone Metastases

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients (NCT03691493)

Summary

To take part in this study you must have estrogen receptor positive, HER2 negative metastatic (stage IV) breast cancer that has spread to the bone.

This study will investigate the effects (good or bad) of using radiation therapy along with the targeted therapy palbociclib (Ibrance®) and hormone therapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Ibrance is a type of targeted therapy called a CDK 4/6 inhibitor. It is used along with a hormone therapy to treat metastatic breast cancer. The hormone therapies used along with Ibrance are fulvestrant (Faslodex®), letrozole (Femara®), anastrozole (Arimidex®), exemestane (Aromasin®) and tamoxifen.


This is a Phase II trial

Gedatolisib, Ibrance and Faslodex Before Surgery in Women With ER+ HER2- Breast Cancer

Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer (NCT02626507)

Summary

To take part in this study you must be a woman with ER-positive HER2-negative stage I, II, III or IV (metastatic) breast cancer who has not yet had any breast cancer treatments and is scheduled to have a lumpectomy or a mastectomy.

The purpose of this study is to test the safety and effects (good or bad) and best dose of the targeted therapy gedatolisib when used along with fulvestrant (Faslodex®) and palbociclib (Ibrance®). The combination is given before surgery. This is called neoadjuvant treatment. Giving therapy before surgery allows researchers to study the effect the therapy has on the breast tumor. Gedatolisib kills cancer cells by blocking the PI3K/mTOR pathway. Faslodex® is a hormone therapy approved to treat advanced breast cancer in postmenopausal women. Ibrance® is a type of targeted therapy called a CDK 4/6 inhibitor. It is approved to treat metastatic breast cancer. If you are premenopausal, you will also be given the drug goserelin (Zoladex®), which will put you in temporary menopause.


This is a Phase I trial

DS-8201a Plus Immunotherapy for HER2 Positive or HER2 Low Expression Advanced Breast Cancer

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer (NCT03523572)

Summary

To take part in this study, you must have HER2 positive or low HER2 expression advanced (some stage III) or metastatic (stage IV) breast cancer that did not respond to standard therapies.

This study will test the safety and effects (good or bad) of an experimental drug called DS-8201 when it is given along with an immunotherapy to treat advanced breast cancer. DS-8201a (Trastuzumab deruxtecan) is a new type of HER2-targeted therapy. It is an antibody-drug conjugate (ADC), which means it uses an antibody to deliver a chemotherapy drug directly to the cancer cells. The immunotherapy being used in this study is the PD-1 inhibitor nivolumab (Opdivo®). By blocking PD-1, it allows your immune system to see and go after cancer cells. It is approved to treat certain types of cancers. Its use in breast cancer is considered experimental.


This is a Phase I-II trial

T-DM1 and Palbociclib for Advanced HER2 Positive Breast Cancer

A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer (NCT03530696)

Summary

To take part in this study you must have metastatic (stage IV) HER2-positive breast cancer.

This study is comparing the side effects and effectiveness of the combination of T-DM1 (Kadcyla®) and palbociclib (Ibrance®) to T-DM1 (Kadcyla®) alone. Kadcyla® is a HER2-targeted therapy that combines the chemotherapy drug DM1 with the HER2 targeted therapy trastuzumab (Herceptin). It is approved for patients with previously treated HER2-positive metastatic breast cancer. Ibrance® is a CDK4/6 inhibitor approved to treat metastatic breast cancer when given along with hormone therapy--either letrozole (Femara®) or fulvestrant (Faslodex®).


This is a Phase II trial

AZD5363 for ER+ Advanced Breast (and Other) Tumors with an AKT Mutation

A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3 (NCT03310541)

Summary

To take part in this study, you must have been diagnosed with ER-positive, advanced (some stage III) or metastatic (stage IV) breast cancer. You must also be postmenopausal, have already been treated with fulvestrant (Faslodex®) and have your tumor test positive for a specific AKT mutation. This study is investigating the safety and best dose of a new targeted therapy when it is given along with Faslodex to treat patients with advanced ER+ breast cancer that has a specific AKT mutation.The new targeted therapy, called AZD5363, works by blocking the AKT1 protein, which plays a role in cancer cell growth. Fulvestrant (Faslodex®) is an anti-estrogen drug used to treat advanced breast cancer. This study is also recruiting women and men with other types of cancer.
This is a Phase I trial

Neratinib plus Faslodex for HER2+, ER+ Advanced Breast Cancer

A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer (NCT03289039)

Summary

To take part in this study, you must have ER-positive, HER2-positive advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of using a newly approved targeted therapy along with a hormone therapy to treat advanced breast cancer. The newly approved targeted therapy is neratinib (Nerlynx®). It is a tyrosine kinase inhibitor that is approved to treat early-stage HER2+ breast cancer. Fulvestrant (Faslodex®) is a hormone therapy approved to treat hormone sensitive metastatic breast cancer in postmenopausal women.
This is a Phase II trial

Genetic Tumor Profiling to Select Targeted Drug to Treat Advanced Breast Cancer

A Basket Study: Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute (NCT03098576)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have had at least one treatment your tumor did not respond to or progressed on. In this study, a sample of your tumor will be analyzed (called molecular profiling) at Cedars-Sinai Medical Center in California to determine which targeted drug could be used as a treatment for your cancer. Molecular profiling is a process that identifies mutations and biomarkers in your tumor's DNA that have FDA-approved matched therapies or are eligible for clinical studies.

SAR439859 with Ibrance in Postmenopausal Women with ER+, HER2- Advanced Breast Cancer

A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer(NCT03284957)

Summary

To take part in this study, you must have ER-positive, HER2-negative, locally advanced (some stage III) or metastatic (stage IV) breast cancer. You must also be postmenopausal and have already received treatment for your breast cancer. This study will determine the best dose, safety and effects (good or bad) of SAR439859 when it is given alone or in combination with palbociclib (Ibrance®). SAR439859 is an experimental anti-estrogen drug. It is available only in clinical trials. Ibrance® is a targeted therapy that blocks the CDK4/6 protein. It is approved to treat postmenopausal women with ER+, HER2- metastatic breast cancer.
This is a Phase I-II trial

MCS110 and PDR001 For Advanced Triple Negative Breast (and Other) Cancer

A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (NCT02807844)

Summary

To take part in this study, you must have advanced triple negative breast cancer and have already been treated with standard treatments or have no standard treatment available. This study is investigating whether it is safe and effective to combine two cancer drugs that work in different ways. The researchers also want to learn more about how these two drugs work together. The two drugs being used in this study are MCS110 and PDR001. MCS110 is a targeted treatment. PDR001 is an immunotherapy drug. Both of these drugs are currently only available in clinical trials. This study is also enrolling patients with advanced pancreatic and endometrial cancers and advanced melanoma (skin cancer).


This is a Phase I-II trial

Kadcyla and Neratinib for Metastatic HER2-Positive Breast Cancer

A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer (NCT02236000)

Summary

Trastuzumab emtansine (T-DM1/Kadcyla®) combines the chemotherapy drug DM1 with the HER2-targeted therapy trastuzumab (Herceptin®). This allows the DM1 to be delivered directly to the cancer cells. It is approved for the treatment of HER2+ metastatic breast cancer in patients who have already received Herceptin and a taxane. Neratinib is a new drug currently being studied for HER2-targeted breast cancer. It works by blocking two receptors, HER2 and EGFR. This study is looking at the safety, best dose, and efficacy of neratinib that can be given with Kadcylato treat HER2-positive metastatic breast cancer that has progressed on prior anti-HER2 based therapy. To be eligible, patients must have had one (and only one) regimen of anti-HER2 based therapy for metastatic disease (dual anti-HER agents may have been given in combination e.g., docetaxel, trastuzumab and pertuzumab).
This is a Phase I-II trial

Keytruda plus Kadcyla for HER2+ Metastatic Breast Cancer

A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer (NCT03032107)

Summary

To take part in this study, you must have HER2-positive metastatic (stage IV) breast cancer. T